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ABSTRACT. 
THE MOLECULAR GENETICS OF TYPE 2 DIABETES. 
PHILIP SAKER, Diabetes Research Laboratories, OXFORD, UK. 
Thesis subm itted for the degree of Doctor of Philosophy, 1995. 
Type 2 diabetes has a substantial genetic component. The aim of this 
dissertation was to investigate the molecular basis of Type 2 diabetes with 
particular emphasis on the role of the glucokinase gene. Other work studied 
specific mutations in the tRNALeu(UUR) gene of mitochondrial DNA and in the 
glucagon receptor gene. 
The Introductory chapter presents an overview of Type 2 diabetes, and the 
influence of the environment and the contribution of genetics to its development. 
It then introduces the molecular biological approach to the study of this disease 
and the function of the J3-cell and the important role of glucokinase in glucose 
homeostasis. 
Chapter 2 gives details of ascertainment criteria for the subjects studied and 
outlines the methodology used to study the molecular genetics of Type 2 
diabetes. The techniques described include DNA extraction, the polymerase 
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chain reaction (PCR), microsatellite markers, restriction fragment length 
polymorph isms (RFLPs), mutation screening, separation of PCR products and 
direct sequencing of them. 
Chapter 3 investigates the role of the glucokinase gene in five pedigrees with 
maturity onset diabetes of the young (MOOY). Using the microsatellite 
polymorph isms GCK1 and GCK2, diabetes was found not to be linked to the 
glucokinase gene in these multi-generation pedigrees. 
Chapter 4 assesses the contribution of the glucokinase gene to Type 2 diabetes 
in the UK Caucasian population by investigating the two microsatellite 
polymorph isms in well-characterised Type 2 diabetic subjects and 
normoglycaemic control subjects. There was no linkage disequilibrium between 
the two polymorphisms, and no association with diabetes was found. This 
suggests that a single mutation in or near the glucokinase gene is not a common 
cause of Type 2 diabetes in this population. 
Chapter 5 describes the development of a robust method to screen for mutations 
using the technique of single-stranded conformational polymorphism (SSCP) 
analysis. Chapter 6 utilises this method, and found that mutations in the 
glucokinase gene can contribute to the pathogenesis of gestational diabetes. 
Four pedigrees from the Oxford district had been found to possess the same 
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missense mutation in the glucokinase gene at position 299. Chapter 7 
establishes that the high prevalence of this glucokinase mutation in this district is 
probably due to a founder-effect, by haplotyping affected members of the four 
pedigrees for GCK1 and GCK2. 
Chapters 8 and 9 use restriction fragment length polymorphism (RFLP) analysis 
to detect specific mutations known to create, or remove a cutting site for a 
restriction endonuclease. Chapter 8 investigates the contribution of the 
mitochondrial transfer RNA (tRNALeu(UUR) mutation at position 3243bp to Type 2 
diabetes. Chapter 9 studies a mutation in the glucagon receptor and its possible 
susceptibility to Type 2 diabetes. 
Chapter 10 concludes the dissertation and outlines future areas for investigation. 
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1.1 TYPE 2 DIABETES. 
Type 2 diabetes is a major cause of morbidity and mortality in both the developed 
and developing world. Morbidity is associated with microvascular, macrovascular 
and neurological diseases, and cardiovascular mortality increase is 2-3 fold. The 
prevalence of the disease varies. In Caucasian populations it ranges between 2-
6010, but in some ethnic groups exceeds 30% (Zimmet 1982). An increase in the 
understanding and pathophysiology of this important disease will allow 
developments in its treatment, and possible prevention (UKPDS VIII). 
Diabetes mellitus is differentiated into two groups; Type 1 diabetes which is due to 
autoimmune destruction of the insulin secreting pancreatic J3-cells. Type 2 
diabetes is not an autoimmune disease, subjects are islet cell antibody negative 
and their hyperglycaemia may initially be controlled with diet and/or tablets, but 
may progress to requiring insulin treatment although they are not insulin-
dependent. Differentiation between the two forms of diabetes has been aided by 
HLA typing and the identification of specific alleles being associated with Type 1 
diabetes (Cudworth et al 1974; Nerup et al 1974). Problems with diagnosis of 
Type 2 diabetes occur as there is no biochemical marker for the disease and 
treatment decisions, particularly with regard to insulin use, are physician 
dependent. Subjects tend to present in middle or old age (age 50-60 years), 
unless they are screened in pregnancy or present with another illness. A large 
number of cases are subclinical and so complications may occur before the 
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diagnosis of diabetes is made. 
Type 2 diabetes arises due to both J3-cell defects and insulin resistance resulting 
in inappropriate insulin secretion for the levels of circulating glucose (DeFronzo et 
al 1988; Eriksson et al 1989). Both of these contribute to Type 2 diabetes, along 
with obesity, and our present knowledge does not enable us to determine that any 
one is the "primary defect" of Type 2 diabetes. Nevertheless, there are some 
subgroups of the disease which are due to only one defect. For example, patients 
with Maturity Onset Diabetes of the Young (MODy) only have a J3-cell defect, and 
do not have increased insulin resistance compared to non-diabetic subjects 
(Hattersley et al 1992b). 
1.2 ENVIRONMENT. 
The environment is an important factor in the development of the disease. 
Improved understanding of its influences will help to define the genetic factors 
with which they interact. 
1.2.1 High risk populations. 
The Pima Indians of Arizona and the Nauruans of Micronesia are two isolated 
populations in whom Type 2 diabetes was previously unknown. Over the last 50 
years it has now reached almost epidemic proportions and has a prevalence of 
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over 30% in adult Pima Indians and Nauruans (Zimmet et aI1981). This increase 
has been associated with dramatic changes in lifestyle. Both populations had 
traditionally been active hunter-gatherers, but due to westernisation have now 
become sedentary, and many are now greatly obese. Studies comparing rural to 
urban migration related differences in prevalence have shown the importance of 
these lifestyle changes (Zimmet et a11983; Taylor et a11985; Serjeantson et al 
1983). There is a higher prevalence of diabetes in subjects living in a modern 
urbanised environment, than those who maintain a relatively traditional lifestyle. 
An urban environment does not result in such a high prevalence in all 
populations, so there must be a difference in susceptibility (Zimmet et al 1983). 
This difference in susceptibility is probably genetic; in high prevalence 
populations the frequency of diabetes declines as the proportion of foreign genes 
increases. In full-blood Nauruans the prevalence of diabetes after the age of 60 
years is 83%, whereas it is 17% in those inhabitants in whom Caucasian ancestral 
gene admixture, assessed by HLA typing, can be demonstrated (Serjeantson et al 
1983). 
JV Neel proposed the "thrifty genotype" to explain the increase in prevalence with 
westernisation. The same gene or genes which gave selective advantage during 
a hunter-gatherer existence where feasting was followed by long periods of 
starvation, are now responsible for the high prevalence of diabetes in an 
environment which now has an abundant supply of food (Neel JV 1962). The 
"thrifty genotype" would favour a highly efficient storage of energy as fat and 
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glycogen which would be detrimental when there is a constant supply of refined 
carbohydrate. The precise pathophysiology of the "thrifty genotype" is poorly 
defined but offers an interesting theory with regards to the relationship between 
inherited and environmental factors in these high prevalence populations. 
1.2.2 Age, Obesity and Physical Activity. 
The incidence of diabetes increases with age in Caucasian populations. This 
could either represent a physiological increase in all population members' glucose 
tolerance or an age-related expression in those members with a genetic 
predisposition. The increase in insulin resistance associated with obesity, 
possibly due in part to the increased supply of non-esterified fatty acids, will 
increase the hyperglycaemia in a subject with Type 2 diabetes. Exercise will 
increase insulin sensitivity and physically fit people have a lower incidence of 
diabetes. It is possible that obesity and a sedentary lifestyle are major 
precipitators of the expression of at-risk genes for diabetes. 
1.2.3 Intrauterine environment. 
Hales et al observed that a low birth weight was associated with glucose 
intolerance in old age in a cohort of men from Hertfordshire. This led to the 
suggestion that intra-uterine environment may be important in the aetiology of 
Type 2 diabetes (Hales et al 1991). It has been proposed that intra-uterine 
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nutrition may affect the development of the foetal pancreas and so alter the adult 
pancreatic reserve, or it may affect insulin resistance. An alternative explanation 
is that the genetic predisposition to diabetes results in reduced foetal size as well 
as the lower birth weight. 
1.2.4 Viral infection. 
Viral infections may have an important role in the progression of Type 1 diabetes. 
Cytomegalovirus (CMV) has been seen with greater frequency in pancreatic 
samples from Type 2 diabetic subjects than pancreatic samples from controls 
(Lohr and Oldstone 1990). It has been proposed that low level chronic infection 
of f3-cells could be responsible for the relative hyposecretion of insulin seen in 
Type 2 diabetic subjects. Hattersley et al failed to replicate the observations and 
suspected that contamination of pancreatic sections had occurred in the original 
study (Hattersley et al 1992a). Viral infection still remains a possible contributor 
to the pathogenesis of Type 2 diabetes, but this remains to be substantiated. 
1.3 GENETICS OF TYPE 2 DIABETES. 
1.3.1 Early Studies. 
Genetic factors contribute to the aetiology of Type 2 diabetes (Kobberling and 
Tillil 1982). Early clinical descriptions reveal that the familial nature of the 
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disease was not recognised. This was probably due to the rarity of the disease at 
the time (Galen only observed two cases during his career), and that most cases 
were likely to be Type 1 diabetes in whom family members are less likely to be 
affected. Sushruta and Charuka in the 5th century AD were probably the first to 
record the familial nature of diabetes (Simpson 1976). In 1696, Richard Morton 
described a pedigree in which 4 out of 7 siblings had diabetes mellitus. He 
concluded that this occurred due to the inheritance of a common familial factor 
predisposing to diabetes. 
Early in the 20th century, it was recognised that a family history of diabetes was 
more common in diabetic patients than non-diabetic patients. Pincus and White 
found a family history in 23% of close relatives of a cohort of 523 diabetic 
patients, as opposed to just 10% in comparable relatives of 153 controls (Pincus 
and White 1933). Cummidge recognised that there were two forms of diabetes 
which probably had two different modes of inheritance (Cummidge et al 1928). 
One form showed dominant inheritance which "is invariably mild and may persist 
for many years", or recessive which "is generally grave from onset". The 
significance of this was not fully appreciated, and studies did not 
differentiate/distinguish between the two forms of diabetes. Differentiating Type 1 
and 2 diabetes was vital in reducing heterogeneity and to clarify the inheritance of 
diabetes. Further observations were reported which were important in separating 
the two forms of diabetes. 
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Harris reported on the family history of a series of 1241 patients from King's 
College Hospital clinics (Harris 1950). He discovered that when two siblings had 
diabetes there was a marked similarity in their age of onset. Siblings of a subject 
with an earlier age of onset were more likely to develop diabetes earlier in their 
life than siblings of late onset subjects. He concluded that there was genetic 
heterogeneity between early and late onset diabetes. 
1.3.2 Studies in Twins. 
Twin studies have provided strong evidence for a major genetic component in 
Type 2 diabetes. Early twin studies had revealed a higher concordance rate (45-
96%) in monozygotic (identical) twins than dizygotic (non-identical) twins (3-37%) 
(reviewed in Barnett et al 1982). The authors did not discriminate between Type 
1 and 2 diabetes, or perform glucose tolerance testing in the "unaffected" twin, 
which makes interpreting these results difficult. The concordance rate would have 
been underestimated, as Type 2 diabetes is often sub-clinical. 
Barnett reported on the King's longitudinal collection of 200 pairs of monozygotic 
twins who had been ascertained by one twin already having diabetes (Barnett et 
al 1981 a). The subjects were sub-divided into Type 1 and 2 diabetes, and regular 
testing of glucose tolerance was carried out. 48/53 (91 %) of Type 2 diabetic twins 
were concordant, in contrast to 80/147 (54%) of Type 1 twins (Barnett et al 
1981 a). In 46/48 concordant Type 2 diabetic twin pairs, the second twin was 
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diagnosed as having diabetes within 10 years of the first. The 5 individuals who 
had been shown to be discordant for over 15 years were shown to have mild 
hyperglycaemia and low insulin responses to an oral glucose load (Barnett et al 
1981 b). These results could reflect early alterations leading to the development 
of Type 2 diabetes, which would suggest that concordance is nearing 100%. The 
authors were aware of selection bias in their study which would favour finding 
concordance. Those cases with both twins affected were more likely to be 
referred to this study than cases where only one twin was affected. 
Newman avoided ascertainment bias by identifying 250 monozygotic and 264 
dizygotic twins through military records, without reference to disease status 
(Newman et al 1987). Only 4/25 twins were concordant for Type 2 diabetes when 
they were first examined at a mean age of 47 years. 10 years later, only 1/15 of 
the originally discordant monozygotic twin pairs retested remained discordant. 
These findings show that if an unaffected monozygotic twin of a Type 2 diabetic 
patient is followed up with glucose tolerance testing for 10 years, there is a high 
probability that they will be diagnosed with diabetes too. 
This data is regarded as strong evidence for a genetic contribution to Type 2 
diabetes. The high concordance in Type 2 diabetes could be due to a shared 
genetic predisposition, or a shared environment. Evidence to support that the 
genetic factors are more important comes from the lower concordance rates seen 
in dizygotic twins (Newman et al 1987), and that twins live apart in their middle 
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and latter lives when Type 2 diabetes is diagnosed (Barnett et al 1981 a; Newman 
et al 1987). The delay in the diagnosis of the second twin suggests that 
environmental factors influence the timing of the onset of diabetes. 
1.4 THE GENETIC NIGHTMARE OF TYPE 2 DIABETES. 
Despite the fact that Type 2 diabetes is a common disease and has been shown 
to have a large genetic component, it has been difficult to identify the genetic 
defects involved in its aetiology. Type 2 diabetes has been described as the 
"genetic nightmare" (Neel 1976; O'Rahilly et al 1988). The study of the molecular 
biology of Type 2 diabetes has been hindered by the heterogeneity of the 
disease, and difficulties in defining affection status, collection of large multi-
generation pedigrees, and defining the pattern of inheritance. Segregation 
analysis has shown that Type 2 diabetes is unlikely to be due to a recessive gene, 
or a single autosomal dominant gene with high penetrance (Cook et al 1993), 
although this may be the case in a minority of pedigrees. It appears to be 
polygenic, although a major gene may be present (Cook et al 1993). 
1.4.1 Collection of large, multi-generation pedigrees. 
The technique of linkage analysis is a very powerful tool defining the molecular 
biology of diseases which is best applied to large multi-generation pedigrees with 
a single gene disease (Ott 1985). Collection of large multi-generation pedigrees 
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is hampered by the late age of onset of the disease and the disease-related 
mortality. Type 2 diabetes usually presents in the 6th decade. Children of 
affected individuals will be in their 30s and 40s at which time it is impossible to 
define if they will go on to develop diabetes in later life. The parents of the 
affected individuals are likely to be in their 70s and 80s and frequently have died. 
The disease-related mortality will mean that the parents are more likely to have 
died if they had suffered from diabetes, whether it had been diagnosed or not. 
There is an approximately two fold increase in mortality in subjects with diabetes 
generally as a result of cardio-vascular deaths (Panzram et al 1987). Probands 
diagnosed before the age of 40 years increases the likelihood that both parents 
will be alive, but the early age of diagnosis of the proband is frequently associated 
with bi-lineal inheritance. O'Rahilly found that in subjects with "early-onset 
diabetes" (diagnosed between the ages of 25 and 40 years), 83% of subjects had 
both parents affected with either diabetes or glucose intolerance (O'Rahilly et al 
1987). Linkage analysis gives very little information, if any, when both of the 
parents are affected. 
1.4.2 Heterogeneity. 
To overcome the problems of collecting large multi-generation pedigrees, an 
alternative is to collect many small nuclear families. This strategy is likely to be 
unsuccessful in Type 2 diabetes as it is heterogeneous, rather then 
homogeneous. The heterogeneity of Type 2 diabetes is already apparent as 
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different genetic causes may have a similar diabetic phenotype including 
haemochromatosis, Turner's syndrome, Prader Willi syndrome and cystic fibrosis 
(Vadheim and Rotter 1992). In rare cases, hyperglycaemia can also occur 
because of mutations of insulin (Steiner et al 1990; Taylor et al 1993), or the 
insulin receptor as in leprechaun syndrome. Within the Type 2 diabetic 
population there is considerable variation in obesity, degree of hyperglycaemia, 
and pathophysiology. Phenotypic variation suggests genetic heterogeneity, but 
this will not be clarified until genetic markers are defined. To reduce the problems 
of heterogeneity specific, well-defined populations may be studied. Examples of 
such subgroups are those with insulin resistance, or maturity onset diabetes of 
the young (MODY). 
MODY has an early age of onset (before the age of 25 years in at least two family 
members), not insulin-dependent (shown by absence of insulin treatment 5 years 
after diagnosis or significant C peptide in a patient on insulin treatment), and 
autosomal dominant inheritance (ie vertical transmission of diabetes through at 
least three generations, ideally with the same phenotype in cousins or second 
cousins) (Hattersley and Tattersall 1995). Physiological studies have shown that 
MODY is a p-cell defect (Tattersall 1975; Fajans 1989; Hattersley et al 1992c). 
Studying the MODY subgroup has the advantages of enabling collection of 
suitable large multi-generation pedigrees, and reducing the amount of genetic 
heterogeneity. 
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1.4.3 Difficulties in defining the affection status. 
To investigate the molecular genetics of a disease such as diabetes, well-
characterised affected and non-affected subjects and collection of large, multi-
generation pedigrees are required for the studies. A particular problem 
encountered with diabetes is that it may be sub-clinical and hence undiagnosed. 
This may alter the conclusions of the genetic study. Therefore, physiological 
studies should accompany genetic studies to aid the biochemical assessment of 
subjects and defining of study populations. 
1.5 MOLECULAR BIOLOGICAL APPROACH. 
The main approach in the investigation of the molecular genetics of Type 2 
diabetes has been the study of candidate genes. Localisation of a candidate 
gene to a particular chromosome through the identification of its cDNA sequence 
enables study of its contribution to the disease. 
1.5.1 Molecular biological markers. 
Molecular genetic studies of Type 2 diabetes have principally used population 
studies and linkage studies. These approaches both utilise molecular markers 
which are shown to be linked to the gene of interest. Restriction fragment length 
polymorph isms (RFLPs), or more recently polymorphic microsatellites which are 
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both located throughout the human genome are used as genetic markers. 
RFLPs are sites within the genome which are recognised by specific restriction 
endonucleases, these enzymes will then cut the genomic sequence. The RFLPs 
are detected as differences in the size of fragments produced after enzyme 
digestion which can be resolved by electrophoresing of DNA on polyacrylamide 
gels followed by Southern blotting, or by peR amplification of a specific restriction 
site and running the digested peR product on agarose gels and ethidium bromide 
staining. 
Microsatellites are di-, tri-, or tetra- nucleotide repeats that show length 
polymorph isms resulting in the variation in the number of repeats. Following 
polymerase chain reaction (peR) amplification of these microsatellite sequences, 
the microsatellite polymorph isms (alleles) are resolved on agarose gels and their 
sizes determined. These microsatellite polymorph isms may be used as markers if 
they are so close as to exclude recombination between themselves and the 
candidate gene. The length polymorphisms (alleles) can then be studied in 
pedigrees and populations, and then assessment made as to whether the 
candidate gene increases susceptibility to disease. 
1.5.2 Linkage analysis. 
Linkage analysis is performed on suitable multi-generation pedigrees to study the 
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co-inheritance of molecular markers with disease. When the marker is in close 
proximity to the candidate gene they will be inherited together. If a particular 
marker allele is found to cosegregate with the disease there could be a defect in 
the candidate gene that is inherited with it. Statistical calculations (LaO scores) 
are carried out to assess whether there is significant linkage of the candidate 
gene to the disease. By convention, a positive LaO score of +3 or greater is 
considered as evidence of linkage, and a LaO score of less than -2 is taken as 
evidence of exclusion of linkage for the particular recombination fraction (8) 
(Lathrop and Laloud 1984). 
1.5.3 Population association studies. 
Population association studies have an important role in determining the genetic 
basis of a disease. Polymorphic molecular markers are used and investigated in 
non-affected (normal) and affected subjects. The frequency of marker alleles or 
haplotypes (linkage of two or more polymorphic sites along a chromosome) are 
compared between the two groups. The frequency of a marker allele will be 
increased in the affected group if that allele is in linkage disequilibrium with a 
common mutation in the candidate gene. Linkage disequilibrium implies that a 
specific disease-causing mutation originally arose in one individual or a small 
population of subjects and that they possessed a specific allele at a nearby 
genetic marker locus. The two loci are physically so close that throughout the 
subsequent generations of descendants these loci have not been separated 
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during meiotic recombinations. The marker may then be used to study the 
association of a particular allele with disease in a population. There are problems 
associated with this type of investigation: 
a. The genetic marker must be tightly linked to the candidate gene. 
b. There must be one or only a few defects in the candidate gene causing the 
disease, otherwise the mutations will be found randomly with different 
alleles of the marker loci. 
c. The mutations must have a recent origin, otherwise the mutations will be 
randomly associated with different alleles of the marker loci. 
d. Affected and non-affected subjects must be from the same ethnic 
population (see Genetic Admixture). 
e. The information acquired is highly dependent on the degree of 
polymorph isms of the marker loci studied. 
1.5.4 Genetic Admixture. 
Genetic admixture is a complicating factor in population association studies. A 
population which appears to be homogeneous may in fact have genetic 
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components from an ethnic group. Any trait at a higher frequency in an ethnic 
group will show positive association with any allele that also happens to be 
common in that group. An example of foreign genetic admixture is seen in 
Nauruans. There is a higher frequency of Type 2 diabetes in full-blooded 
Nauruans compared to those with Caucasian ancestral gene admixture, as 
assessed by HLA typing. Therefore, any polymorphism that is of a higher 
frequency in Nauruans compared to Caucasians will be associated with diabetes. 
To reduce the risk of obtaining an incorrect association, the following steps may 
be taken: 
a. they should be performed in a homogeneous population. 
b. use an "internal control" for allele frequencies. This studies the inheritance 
of alleles in affected individuals and their parents (transmission distribution 
of kin test) 
c. perform a transmission disequilibrium test (TOT). This assumes that a 
parent heterozygous for an associated allele (A) and a non-associated 
allele (a), should transmit (A) more often than (a) to an affected subject. 
1.5.5 Mutation screening. 
Sequencing is the most accurate method of identifying mutations in candidate 
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genes, but this is time-consuming, expensive and laborious. Rapid methods of 
screening subjects to detect those which may possess a mutation can be 
employed prior to sequencing. The most frequently used method is to screen for 
single-stranded conformational polymorph isms (SSCP) (Orita et al 1989). A 
region of DNA is amplified (usually exons) using PCR, the product is heated to 
denature it to single strands, and then run on a non-denaturing gel. The base 
sequence of the single-stranded DNA will determine the secondary structure, this 
will affect its mobility on the gel. Mutations are detected as differences in mobility 
of the sample on the gel. SSCP is rapid and allows the detection of mutations 
even in the presence of heterogeneity. It is unlikely to detect all mutations but 
under optimal controlled conditions it is reported to have a sensitivity of between 
68 - 99%) (Orita et al 1989; Sheffield et al 1993). Once an SSCP variant is found 
sequencing of the DNA is undertaken to identify the base change responsible 
which may help to determine whether it is a polymorphism or mutation. A silent 
polymorphism is clearly unlikely to be the cause of disease. Sequence variations 
which alter a coding region may still not be the causative mutation. The 
contribution of the mutation to the disease will still need to be determined. 
1.5.5 Biological significance of a mutation. 
Silent polymorphisms are unlikely to be the cause of a disease. Some sequence 
variations such as frame shifts, or chain terminations, are obviously deleterious to 
a protein. Other alterations such as missense mutations leading to amino acid 
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substitutions, or base changes within introns, can be either functionally relevant or 
sequence polymorphisms. To determine whether a sequence alteration is 
pathogenic, family studies, population studies and functional assays after in vitro 
expression may be required. 
Many candidate genes and their role in diabetes mellitus have been considered. 
The main part of my thesis concentrates on the contribution of defects in the 
glucokinase gene to Type 2 diabetes, with additional data on mitochondrial DNA 
and the glucagon-receptor gene. These are reviewed in the following sections. 
1.6 THE Ji-CELL AND THE ROLE OF GLUCOKINASE IN INSULIN SECRETION. 
Glucose homeostasis is regulated by insulin; the secretion of insulin from the 
pancreatic Ji-cell is itself regulated by plasma glucose concentrations within a 
negative feedback mechanism. In a normal subject, insulin is secreted 
appropriate to the levels of circulating glucose. This prevents wild fluctuations in 
the levels of glucose and the effects of complications from hypo and 
hyperglycaemia. 
Glucokinase (Gel<) is an important enzyme in the regulation of glucose 
metabolism in the pancreatic islets and liver, and has been described as the 
"pancreatic glucose sensor" (Matschinsky 1990). Glucokinase catalyses the 
phosphorylation of glucose to glucose-6 phosphate, the first step in the glycolytic 
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pathway. 
Glucokinase (ATP: D-hexose-6-phosphotransferase; EC 2.7.1.1.) is a member 
(hexokinase IV) of a family of hexokinases (I-IV). It is distinguishable from the 
other hexokinases by its lower molecular weight, higher Km for glucose (SmM) 
which is in the physiological range (4-15 mM), sigmoid glucose - reaction velocity 
relationship (Hill coeffecient 1.6) and by its lack of product inhibition by glucose-6-
phosphate. These unique kinetic properties result in glucose phosphorylation 
maintaining a gradient for glucose transport, and allows the f3-cell and 
hepatocytes to respond appropriately to the degree of hyperglycaemia 
(Matschinsky 1990; Meglasson and Matschinsky 1986). 
Glucose is passively transported into the pancreatic f3-cell down its concentration 
gradient by the liverlislet glucose transporter (Glut 2). Glucokinase then 
catalyses the phosphorylation of glucose, producing glucose-6-phosphate. This 
product is metabolised by glycolysis and then progresses from the cytoplasm to 
the mitochondria where oxidative phosphorylation occurs. This results in the 
elevation of the ratio of ATP/ADP concentrations, catalysing the closure of the 
ATP-dependent potassium channels in the cell membrane (Ashcroft and Ashcroft 
1992). Depolarisation of the cell membrane causes the opening of the voltage-
dependent calcium channels. The intracellular calcium levels increase which 
leads to exocytosis of insulin granules (Figure 1.6). Glucose concentration is the 
major regulator of glucokinase expression within the f3-cell (Magnuson 1990). 
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Hyperglycaemia will increase expression of glucokinase and hence its activity, 
this then results in an increase in insulin secretion. 
The primary response of the liver to hyperglycaemia is an increase in the uptake 
of glucose and the synthesis of glycogen. This is partly regulated by glucokinase 
(Matschinsky 1990). Glucose phosphorylation maintains a concentration gradient 
for glucose transportation across the cell membrane via Glut 2. This enables 
glucose uptake by the liver and its metabolism to glycogen. Expression of 
glucokinase within the liver is increased in response to an elevation in insulin 
levels (Magnuson 1990), which results in an increase in hepatic glucose uptake 
following meals. 
Glucokinase is a good candidate gene for Type 2 diabetes. It is only expressed in 
pancreatic f3-cells and liver hepatocytes, this is tightly controlled by two tissue-
specific promoters. There are 3 glucokinase mRNA isoforms (1 for f3-cells & 2 for 
liver) which are formed by the differential splicing of mRNA. Mutations in this 
gene which could cause alterations in the structure and function of the enzyme it 
codes for may have a profound effect on its capability to act as the "pancreatic 
glucose sensor". Defects in the glucokinase enzyme could reduce the ability of 
the pancreatic f3-cell islets and liver hepatocytes to respond to fluctuations in 
plasma glucose and maintain the body's glucose homeostasis. 
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1.7 THE CONTRIBUTION OF THE GLUCOKINASE GENE TO TYPE 2 
DIABETES. 
The cDNA sequence of glucokinase in the rat was identified in 1989 (Matschinsky 
et al 1989). It was found that there were tissue-specific isoforms which differed in 
exon 1 (Magnuson and Shelton 1989; Magnuson et al 1989). This meant that 
differential expression in the pancreatic p-cells and liver hepatocytes was 
possible, regulated by glucose. These findings brought the possibility of 
molecular biological and genetic studies to determine whether defects in the 
glucokinase gene had a role in Type 2 diabetes. A microsatellite polymorphism in 
the form a of a dinucleotide repeat (CA) tightly linked to the glucokinase gene 
n 
was identified (Matsutani et al 1992). This enabled linkage studies and 
population association studies to be carried out. 
Tight linkage of the glucokinase gene with Type 2 diabetes was found in 
pedigrees with maturity onset diabetes of the young (Froguel et al 1992; 
Hattersley et al 1992b). Mutations of the glucokinase gene were subsequently 
identified in affected subjects (Vionnet et al 1992; Stoffel et al 1992b). A 
missense mutation in exon 8, resulting in the substitution of Glj99 ~Arg, was 
found in Pedigree BX. This same mutation was found in subjects from a classical 
Type 2 diabetic family (Pedigree AX), after a member was picked up on screening 
of 100 English Caucasian subjects with Type 2 diabetes. Screening of 100 
unrelated non-diabetic subjects failed to find this mutation, thus strengthening the 
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conclusion that this mutation was the cause of diabetes (Stoffel et al 1992b). 
Modelling of human glucokinase, using the related yeast hexokinase, has shown 
that exon 8 codes for a region of the enzyme which leads to the cleft of the active 
site where glucose is bound to enable the catalysation of phosphorylation (Gidh-
Jain et al 1992; StCharles et al 1994). Expression studies in E.coli have shown 
that this missense mutation in exon 8 reduces the affinity (Km) of the enzyme for 
glucose to less than 1 % of that for the native form (Gidh-Jain et al 1992). 
Glucokinase mutations have been found in subjects in a Japanese pedigree with 
early-onset Type 2 diabetes (Sakura et al 1992) and with late-onset Type 2 
diabetes (Katagiri et al 1992). The phenotypes of these subjects is similar to that 
seen in the British and French MODY pedigrees. The difference in the age of 
diagnosis and hence classification is probably due to later glucose tolerance 
testing rather than a different phenotype. 
Positive population association studies with GCK1 in Mauritian Creoles and Black 
Americans (Chiu et al 1992a & b) have been published; these suggest a role for 
defects in the Glucokinase gene in the development of Type 2 diabetes. Another 
polymorphism in tight linkage to the GCK gene has been found (GCK 2) (Nishi et 
al 1992) which may be used as a marker for the gene. When used in tandem with 
GCK 1, haplotypes may be constructed when a subject is homozygous at one or 
more loci. This increases the power of population association studies and allows 
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Figure 1.6 Diagram of ~-cell showing the role of glucokinase. 
Glucose t > GIUCOr -6- P 
Glucokinase 
Glucose 
Glycolysis 
;,calCium 
Insulin +- Ca2+ 
Beta cell 
This schematic diagram shows the pathway linking glucose with insulin release in 
the pancreatic B-cell showing the central role of glucokinase. 
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linkage disequilibrium between the two markers to be assessed. 
1.8 MITOCHONDRIAL DNA AND THE tRNALeu(UUR) MUTATION AT POSITION 
3243BP. 
Mitochondria are organelles within cells which contain their own DNA. Each cell 
contains thousands of mitochondria and each mitochondrion contains 2-10 copies 
of mitochondrial DNA (mtDNA). One theory of evolution suggests that 
mitochondria were previously separate, they were engulfed by cells and 
embarked on a symbiotic relationship. Human mtDNA is circular, consisting of 
16,595 bp and has been fully sequenced (Anderson et aI1981). It encodes 13 
subunits of the respiratory chain and oxidative phosphorylation enzymes, 22 
transfer RNAs (tRNAs) and 2 ribosomal RNAs (rRNAs). mtDNA is exclusively 
maternally inherited, probably because sperm contribute almost no cytoplasm to 
the zygote, as the tail is lost at fertilisation (Giles et al 1980). 
The mitochondrial tRNALeu(UUR) mutation at position 3243 bp, resulting in a G~A 
substitution, has been shown to occur within pedigrees with myoencephalopathy 
with lactic acidosis and stroke-like episodes (MELAS), and also in some subjects 
with chronic progressive external opthalmoplegia (ePEO) and in Kearns-Sayre 
syndrome (KSS) (Goto et al 1990). Subsequently, this same mutation was found 
to be present in a pedigree whose affected members had diabetes and/or 
deafness with a maternal mode of inheritance (van den Ouweland 1992. Other 
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similar pedigrees have since been reported (Reardon et al 1992; Kadowaki et al 
1993; Remes et al 1993; Alcolado et al 1994; Katagiri et al 1994). The 
differences in the diseases and the clinical phenotypes shown may be due to 
several factors, including the degree of heteroplasmy. Normal and mutant mtDNA 
are present in the same tissue, and the proportion of mutant mtDNA varies 
between tissues and individuals. There may also be an effect with nuclear-
encoded mitochondrial enzymes. 
Mutations in mitochondrial DNA are thought to affect glucose homeostasis. Under 
aerobic conditions, 95% of ATP synthesis in p-cells is supplied by the 
mitchondrial respiratory chain. An increase in the ATP/ADP ratio within the p-cell 
results in closure of the ATP-dependent potassium channels in the cell 
membrane. Depolarisation of the cell membrane opens the voltage-dependent 
calcium channels. The intracellular calcium levels increase which leads to 
exocytosis of insulin granules. Defects in mitochondria may affect this process 
and lead to diabetes mellitus. The prevalence of the tRNALeu(UUR) mutation at 
position 3243 bp within the UK Type 2 diabetic population needs to be assessed. 
1.9 A HETEROZYGOUS POINT MUTATION IN THE GLUCAGON RECEPTOR 
GENE. 
Glucagon has an important role in the regulation of hepatic glucose production 
and also has a minor role in the regulation of insulin secretion. Glucagon action 
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is mediated via its binding to a specific receptor belonging to the superfamily of G 
protein-coupled transmembrane receptors. Mutations in the glucagon receptor 
gene located on chromosome 17q25 may therefore contribute to Type 2 diabetes. 
A point mutation in exon 2 (Gly4o ~Ser) has been found to be associated with 
Type 2 diabetes in French familial subjects (Hager et aI1995). Receptor binding 
studies found that this mutation results in a 67%, reduction in the affinity for the 
binding of glucagon compared to the "wild-type". The physiological model is 
difficult to interpret, but this mutation may playa role in the development of Type 2 
diabetes. This association study needs to be replicated in an independent cohort, 
and further studies are required to clarify the contribution of this mutation to Type 
2 diabetes. 
1.10 AIMS OF THIS THESIS. 
The major questions that the work in this thesis set out to answer were: 
1. To establish whether diabetes was linked to the glucokinase gene in five 
MODY pedigrees. 
2. To assess the contribution of the glucokinase gene to Type 2 diabetes by 
performing a population association. 
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3. Development of single-stranded conformational polymorphism analysis, 
and consequently to assess the contribution of glucokinase mutations to 
gestational diabetes. 
4. To investigate the prevalence of the previously described mitochondrial 
transfer mutation at position 3243bp, and assess its contribution to Type 2 
diabetes, MODY and gestational diabetes in UK Caucasian subjects. 
5. To investigate the prevalence of the previously described mutation in the 
glucagon-receptor and assess its role in Type 2 diabetes. 
41 
CHAPTER 2 
METHODS 
2.1 SUBJECTS STUDIED 
2.1.1 Introduction 
2.1.2 Pedigree selection criteria 
2.1.3 Additional criteria for defining MODY pedigrees 
2.1.4 Ascertainment of pedigrees 
2.1.5 Random Type 2 diabetic subjects 
2.1.6 Gestational diabetic subjects 
2.1.7 Fasting hyperglycaemic subjects 
2.1.8 Normoglycaemic control subjects 
2.2 PREPARATION OF GENOMIC DNA FROM PERIPHERAL WHOLE 
BLOOD 
2.3 DNA EXTRACTION USING NUCLEON 
2.4 THE POLYMERASE CHAIN REACTION 
2.4.1 Introduction 
2.4.2 Preventing contamination 
2.4.3 Design of oligonucleotide primers 
2.4.4 Visualisation of PCR product 
2.5 MICROSATELLITE MARKERS 
2.5.1 Introduction 
2.5.2 Microsatellite polymorph isms of the glucokinase gene 
42 
2.6 POLYACRYLAMIDE GEL PREPARATION 
2.7 RESTRICTION ENDONUCLEASES 
2.7.1 Reaction mixture for Hha1, Pst1 and Sph1 
2.7.2 Reaction mixture for Apa1 
2.7.3 Restriction analysis to detect the glucokinase missense 
mutation Glj99 ~Arg 
2.7.4 Restriction analysis to detect the mitochondrial DNA mutation of 
tRNA Leu(UUR) at position 3243bp 
2.7.5 Restriction analysis to detect the point mutation Gly4°~Ser in 
the glucagon receptor gene 
2.8 MUTATION SCREENING USING SINGLE-STRANDED 
CONFORMATIONAL POLYMORPHISMS (SSCP) 
2.8.1 Method 
2.8.2 Preparation of polyacrylamide gels 
2.8.3 Sample preparation 
2.8.4 Silver staining 
2.8.5 Mutation screening of the glucokinase gene using SSCP 
2.9 SEPARATION OF PCR AMPLIFICATION PRODUCTS USING 
MAGNETIC DYNAL BEADS IN PREPARATION FOR DIRECT 
SEQUENCING 
2.9.1 Preparation of single-stranded template 
2.10 SEQUENCING SINGLE-STRANDED DNA 
2.10.1 General 
43 
1.10.2 Annealing 
2.10.3 Preparation for the next steps 
2.10.4 Labelling 
2.10.5 Chain termination reaction 
2.10.6 Sequencing gel 
2.10.7 Gel solution 
2.10.8 Running of sequencing gel 
2.10.9 Preparing gel for exposure 
2.11 SEQUENCING OF THE GLUCOKINASE GENE 
44 
2.1 SUBJECTS STUDIED. 
2.1.1 Introduction. 
The subjects studied in the investigations in this dissertation were members of 
Type 2 diabetic and MODY pedigrees, random Type 2 diabetic subjects, 
gestational diabetic subjects, fasting hyperglycaemic subjects, and 
normoglycaemic subjects. This section outlines the selection criteria for these 
groups. 
2.1.2 Pedigree selection criteria. 
Pedigree members were considered affected if they: 
1 had been diagnosed as having diabetes by WHO criteria (fpg >7.Bmmolll, 
or 2 hour post glucose load plasma glucose of >11.2mmolll), and were on 
therapy with oral hypoglycaemic agents, insulin or as a specific diet. 
2 had a fasting plasma glucose concentration >6 mmol/l, which is >3 
standard deviations above the mean of a normal population. 
3 had a plasma glucose >9.3 mmol/l, one hour after a continuous infusion 
of glucose Smg/kg ideal weight per minute. 
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Pedigree members were considered unaffected if they had a fasting plasma 
glucose <6mmol/l or had a plasma glucose <9.3 mmol/l, one hour after a 
continuous infusion of glucose 5 mg/kg ideal weight per minute. As this disease 
has a late age of onset the diagnostic certainty of a normal test increases with 
age and this was taken into account in the computation of penetrances for linkage 
analysis. 
2.1.3 Additional criteria for defining MODY pedigrees. 
1 age at diagnosis of at least two affected members of the family was <25 
years. 
2 diabetes could be treated for at least 2 years without insulin. 
3 the occurrence of diabetes in a family was suggestive of an autosomal 
dominant mode of inheritance (at least three generations of diabetes, 
and/or second cousins with Type 2 diabetes before the age of 25 years). 
2.1.4 Ascertainment of pedigrees. 
3 large pedigrees with MODY (8X, H, A) and a large pedigree with Type 2 
diabetes (AX) were ascertained as part of a large UK study based from Oxford. 
All participating members gave informed consent. Probands were obtained 
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through a diabetic clinic and all relatives known to have diabetes were contacted 
and asked to provide a blood sample for fasting plasma glucose and DNA 
extraction. Their medical records were examined where possible. All other 
pedigree members were tested with either a fasting plasma glucose or a 
continuous infusion of glucose test. The majority of samples were collected by Dr 
AT Hattersley. 
The MODY pedigree M was obtained through Dr Peter Watkins, King's College 
Hospital, and is one of the three original MODY pedigrees described by Professor 
Robert Tattersall. 
The MODY pedigree EA has members residing in Edinburgh and Australia and 
was recruited by Dr MacKie and Dr J Baird. Samples from the Australian branch 
of the pedigree were obtained by Dr RC Turner. 
Pedigree N was obtained from Cambridgeshire through Dr S O'Rahilly. 
2.1.5 Random Type 2 diabetic subjects. 
Blood samples were obtained from unrelated Caucasian Type 2 diabetic subjects 
from the UK Prospective Diabetes Study cohort and DNA was extracted. The 
subjects had newly diagnosed diabetes, age range 25-65 years inclusive (mean 
age 52 years ),with fasting plasma glucose >6mmol/l on two separate occasions 
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mean 11.4mmol/l (UKPDS VIII, 1991). 
2.1.6 Gestational diabetic subjects. 
50 unrelated Caucasian subjects from the Oxford region who had Gestational 
diabetes were studied. Gestational diabetes was diagnosed on the basis of 2 
abnormal oral glucose tolerance test (OGTI) values during pregnancy (28-34 
weeks) by Mr Mike Gillmer, and with hyperglycaemia (>5.5 mmol/l <10 mmol/l) on 
follow up (mean 10 years). Subjects known to be members of pedigrees AX and 
BX were excluded from the study. 
2.1.7 Fasting hyperglycaemic subjects. 
DNA was extracted from blood samples from 100 subjects registered with the 
Oxford clinic of the Fasting Hyperglycaemia Study. Their fasting plasma glucose 
concentration was >5.5mmol/l and <7.8 mmol/l on two separate occasions. 
2.1.8 Normoglycaemic control subjects. 
DNA was extracted from blood samples obtained from 150 healthy Caucasian 
individuals recruited via the UKPDS. These subjects had no family history of 
diabetes and a fasting plasma glucose concentration <5.5 mmoi/i. 
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2.2 PREPARATION OF GENOMIC DNA FROM PERIPHERAL WHOLE BLOOD. 
1. Peripheral whole blood samples were collected in tubes containing 
either Sodium Heparin, or EDTA as anti-coagulant. 
2. The samples were spun in a MSE refrigerated centrifuge at 1500g for 
20 minutes at 4°C. 
3. The plasma was then removed using a disposable pipette and 
discarded. The remaining cells were either stored at -20°C for 
processing later, or processed immediately. 
4. The cells from the sample were transferred to a 50ml centrifuge tube. 
5. To lyse the red cells 45ml of distilled water was added. 
6. The tube was capped and whirlimixed, then centrifuged at 1500g for 15 
minutes at 4°C. 
7. The supernatant was carefully poured away. 
8. 10 ml of 0.1 % NP40 solution was added to the nuclear pellet. 
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9. Steps 6 and 7 were repeated. 
10. 10 ml of lysis buffer was added to the pellet and then capped and 
whirlimixed. 
11. 100f.l1 of 10% SDS and 100mg of Proteinase K (1 mg/ml) were added. 
12. The tube was capped and the contents mixed gently by inverting, then 
incubated at 37°C for a period of 4 - 6 hours. 
13. 2ml of 5x ANE was added. 
14. 0.5 volumes of Tris- saturated phenol and 0.5 volumes of chloroform in 
amyl alcohol (CIAA) were added. 
15. The tube was capped and the contents mixed thoroughly by inversion, 
then centrifuged at 1500g for 15 minutes at 4°C. 
16. The aqueous layer was transferred into a clean 50ml centrifuge tube 
using a glass pipette. 
17. Steps 14, 15 and 16 were repeated. 
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18. 1.0 volumes of CIAA was added to remove any contaminating phenol. 
19. Steps 15 and 16 were repeated. 
20. The DNA was precipitated by adding 0.1 volumes of 4M NaCI and 2.0 
volumes of ethanol. 
21. The tube was then capped and the contents mixed thoroughly by 
inversion, it was then incubated at -20°C for approximately 30 
minutes. 
22. The DNA was pelleted by centrifuging at 1500g for a minimum of 30 
minutes at 4°C (the length of centrifugation will affect the yield). 
23. The supernatant was gently poured off and discarded. The tube was 
inverted and the pellet left to dry at room temperature. 
24. The DNA pellet was dissolved overnight at 4°C in sterilised distilled water 
(the volume depends on the yield). 
25. The quantity and purity of DNA was determined UV 
spectrophotometrically. The 00 at 260nm gives an indication of the 
quantity. The ratio of the 00 at 260nm and 280nm (00260'00280) gives 
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an indication of the purity. A ratio of 1.8 or greater indicates a pure 
preparation of DNA, a ratio significantly less than 1.8 indicates 
contamination with protein. 
25. The DNA sample was aliquoted into labelled 0.5ml centrifuge tubes and 
stored at -20°C. 
2.3 DNA EXTRACTION USING NUCLEON. 
1 Pour blood (about 5-10 ml) into a 50 ml Falcon tube. Add reagent A 
(10 mM Tris-HCI, 320 mM sucrose,S mM MgCI2 , 1 % Triton X-100; adjust to 
pH 8.0 with 2M NaOH) mix by vortexing, and allow to stand for 3-4 min. 
2. Spin 2300 rpm, 4 min, and discard supernatant. 
3. Add 40 ml reagent A, resuspend pellet by vortexing thoroughly, allow to 
stand for 4 min and repeat step 2. 
4. Add 2.5 ml reagent B (400 mM Tris-HCI, adjust to pH to 8.0 with 2M 
NaOH, 60 mM EDTA, 150 mM NaCI, 1% SDS). 
5. Vortex thoroughly to resuspend the pellet and pour into a 5 ml tube. Add 
52 
700JlI sodium perchlorate (5M) and rotary mix at room temperature for 
15 min. 
6. Incubate 25 min, 65°C, and invert at least twice during this time. 
7. Add 2.5 ml chloroform (kept at -20°C). Rotary mix for 10 min, then 
centrifuge at 2,500 rpm for 1 min. 
8. Add 400JlI nucleon silica suspension drop by drop, do not mix, then 
centrifuge at 4,000 rpm for 3 min. 
9. Decant the upper layer into a new 5 ml tube, and centrifuge at 4,000 rpm, 2 
min. 
10. Remove the solution into a new 50 ml Falcon tube and add two volumes 
of cold absolute ethanol. Incubate at -20°C, 15 min, then pick out DNA 
using a hooked Pasteur pipette, place in 200JlI sterile distilled water, and 
allow to resuspend overnight. 
11. Read absorbance at 260 and 280 nm. Use 10JlI DNA solution in 290JlI 
water. Multiply value at 260 nm by 1.5 to get DNA concentration in JlglJlI. 
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2.4 THE POLYMERASE CHAIN REACTION (PCR). 
2.4.1 Introduction. 
peR is an in vitro method of nucleic acid synthesis by which a particular segment 
of DNA can be specifically replicated (Saiki et ai, 1985; Mullis and Faloona, 
1987). The reaction requires double-stranded template DNA, synthetic 
oligonucleotide primers, deoxynucleotide triphosphates to provide both energy 
and nucleotides for DNA synthesis, DNA polymerase, and reaction buffer 
containing magnesium ions. It involves repeated cycles of denaturation of the 
double-stranded DNA, annealing of the primers to their complimentary 
sequences, and extension of the annealed primers with DNA polymerase. The 
primers are designed to anneal to opposite strands of the DNA so that they flank 
the target segment. They dictate the direction of synthesis, and guide the 
polymerisation to produce two copies of the target segment from one double-
stranded DNA template. The resultant copies are complimentary and are capable 
of binding primers, they will themselves act as template for further amplification. 
Thus successive cycles will theoretically double the amount of target DNA 
synthesised in the previous cycle. This results in the exponential amplification of 
the specific target segment, approximately 2n, where n is the number of cycles of 
amplification completed. 
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2.4.2 Preventing Contamination. 
peR is efficient, and has the potential to produce 1 x 106 copies from a single 
copy of target DNA. There is therefore the possibility of contamination producing 
a false-positive amplification. Airborne contamination such as sloughed off skin 
cells or hair roots are ordinarily not a problem. A minute contribution of foreign 
DNA to the reaction is unlikely to have much effect, unless a single cell is being 
used as target DNA. Under normal conditions the greatest risk comes from the 
introduction of previously amplified DNA into the new reaction. 
The following steps are taken to avoid contamination: 
1. Sterilisation of pipette tips, tubes and reagents. 
2. Separate pipettes were designated for preparing peR reagents and 
reactions, and were kept away from areas where products were 
handled. 
3. An area was designated for preparing peR reactions, which was away 
from areas for DNA extractions, and the handling of peR products. 
4. Reagents and primers were aliquoted. 
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5. To minimise the handling of the solutions and reduce the number of 
pipetting steps, a "master mix" was prepared when many identical 
amplifications were to be performed. 
6. For each 'master mix', a water blank containing no DNA was run with 
every PCR amplification to test for the absence of contamination. 
2.4.3 Design of oligonucleotide primers. 
The design of primers is empirical. There are no "hard and fast" rules that will 
produce an efficient primer pair, although there are some general guidelines: 
1. If possible, the average G and C content of the primers should be around 
50% with a random base distribution. 
2. The primers are checked for complimentarity. Particular attention is paid 
to avoid primers with 3' overlaps, thus avoiding "primer-dimer" artefacts. 
3. Primers were designed 20 - 30 bases in length. 
2.4.4 Visualisation of peR product. 
After completion of PCR, the product was run out on a 1.5% agarose gel to 
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ensure that amplification of the target DNA had occurred. 
1. A 100ml gel was prepared with Seakem agarose (Flowgen) in 1 x TBE 
buffer in a conical flask. Ethidium bromide (0.4f.!g/ml) was added to the 
agarose solution and mixed by gentle swirling of the flask. The gel was 
poured and allowed to set with the combs inserted. 
2. The gel was submerged in an electrophoresis tank (Flowgen) filled with 1 x 
TBE buffer. 
3. 2f.!1 of Bromophenol blue loading dye was pipetted into 1.Sml tubes. 
4. Sf.!1 of PCR product from each sample was then pipetted into a separate 
tube with the loading dye. 
S. The 8f.!1 of sample was then loaded into the wells of the gel. 
S. The gel was run at 1S0V (1 OV per cm) for 30 minutes. 
7. The DNA fragments were then visualised on a UV transilluminator (Vilber 
Lourmat Ltd) and photographed with a Polaroid CUS camera. The 
photograph was kept for documentation. 
57 
2.5 MICROSATELLITE MARKERS. 
2.5.1 Introduction. 
Within the genome are interspersed repetitive DNA sequences which have the 
form of a dinucleotide repeat such as (CA)n and (GA)n, trinucleotide repeats and 
tetranucleotide repeats. These DNA sequences have been shown to exhibit 
length polymorph isms which are termed microsatellite polymorph isms (Weber and 
May 1989; Litt and Luty 1989; Economou 1990). 
Microsatellite polymorph isms can provide important information as they may be 
used as genetic markers if they are found to be linked to a particular gene of 
interest. These microsatellite polymorphisms can be analysed once the sequence 
surrounding them has been determined. PCR primers may then be designed 
which are unique to the region flanking the repeats. The region of DNA can then 
be amplified and the sizes of the amplified fragments can be determined by 
running them on non-denaturing polyacrylamide gels. 
2.5.2 Microsatellite polymorphisms of the glucokinase gene. 
To study the glucokinase gene we used two microsatellite polymorph isms, GCK1 
and GCK2, which flank the gene (Figure 2.5.2.1). GCK1 is a repeat sequence of 
the form (CT)n (CA)n approximately 10kb 3' to the glucokinase gene. GCK2 is a 
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Figure 2.5.2.1 Schematic diagram showing the organisation of the glucokinase gene and the position of the 
5' 
microsatellite polymorphisms GCK 1 and GCK2. 
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Exons of the glucokinase gene are indicated by vertical lines and numbers. 
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repeat sequence of the form (CT)n (CA)n approximately 6kb 5' to the glucokinase 
gene. 
PCR amplification was performed using the following primers: 
GCK1 9509 5' ITG GTC AGT GTA GGC TGAACT CAT G 3' 
9510 5' CCC ACA CCA AAA CTG CCT GTA ITA G 3' 
GCK2 hGK-CA1 5' AAC AGA TAC GCT TCA TCC TG 3' 
hGK-CA2 5' TGT CTG CAA CIT ACT CIT AC 3' 
After PCR amplification, and conformation of product, sample was loaded onto an 
80/0 polyacrylamide gel. Generally 6J.!I of sample was added to 3J.!I of 
bromophenol blue dye. If the PCR product is weak or the bands visualised on the 
polyacrylamide are too feint to score and have to be repeated, more product can 
be loaded. 
To aid scoring of alleles, a molecular weight marker is run, or a sample of a 
known genotype. Alternatively sample from pedigree members may be run 
alongside each other and the relationship of the alleles assessed when scoring. 
Figure 2.5.2.2 shows alleles of GCK1. 
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Figure 2.5.2.2 Agarose gel stained with ethidium bromide and showing 
alleles of GCK1. 
M 
M - molecular weight marker. 
_z+2 
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2.6 Polyacrylamide gel preparation. 
10 X TBE 
distilled water 
19: 1 acrylamide/bis 
TEMED 
25% ammonium persulphate 
3ml 
21.ml 
6ml 
24~1 
190~1 
1. Clean glass plates with ethanol and distilled water. 
2. Arrange glass plates in BioRad Protean II electrophoresis apparatus. 
3. Add gel components together in a glass beaker and mix. 
4. Pour gels between glass plates of Protean II system using a 50ml plastic 
syringe. 
5. Gels are left for 2 hours to polymerise at RT 
6. Pre-run gels at 1 OOV for 30 minutes. 
7. Load samples and run-in at 200v for 10 minutes. 
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8. Adjust current to 100V and run for 18 hours. 
9. Alleles were detected by ethidium bromide staining (1S0JlI of 1.1 M ethidium 
bromide diluted in SOOml of distilled water) for approximately 15 
minutes. 
10. Alleles were visualised with UV light (Vilber Lourmat, Ltd.), and 
photographically recorded using a CUS Polaroid camera and film. 
11. Samples were then assigned with alleles of the microsatellite 
polymorphisms. 
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2.7 RESTRICTION ENDONUCLEASES. 
Restriction endonucleases are enzymes which cut DNA at a specific recognition 
sequence. They are used in restriction fragment length polymorphism (RFLP) 
analysis. 
The following restriction endonucleases were used in my work: 
Restriction Recognition site Application 
endonuclease 
Hha 1 To identify the missense mutation Glj99 ~Arg in 
(or Cfo 1) GCG/C exon 8 of the glucokinase gene. 
Pst 1 To divide exons 5 and 6 of the glucokinase 
CTGCAIG gene after PCR. These exons are amplified 
together as they are too close to design primers 
to amplify them individually. 
Sph 1 To divide exon 9 of the glucokinase gene into 
GCATG/C two fragments (205bp and 162bp) after PCR, as 
the product of 367bp is too large to satisfactorily 
run on an SSCP gel. 
Apa 1 Used to identify the tRNA(LeuuuR) at position 
GGGCC/C 3243bp of mitochondrial DNA. 
BstEIl Used to identify the point mutation Gly40 ~Ser in 
G/GTNACC the glucagon receptor (GCG-R) gene 
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2.7.1 Reaction mixture for Hha 1, Pst 1 and Sph 1 (may be made as a master 
mix). 
Per sample: 
distilled water 7~1 
10 X reaction buffer 2~1 
1 OU/~I restriction enzyme 1 ~I 
Then add 10JlI of PCR product, and incubate at 37°C for 2 hours to allow 
digestion. 
For identifying the exon 8 mutation with Hha 1, digestion product was visualised 
on a 2%) agarose gel with ethidium bromide staining. 1 O~I of digestion product 
was added to 4JlI of bromophenol blue dye. The total volume of 14~1 loaded onto 
the gel, and run at 10V/cm until adequate separation had occurred. PCR product 
from a member of Pedigree BX possessing the mutation was digested and run as 
a positive control. The gel was visualised under UV light and photographically 
documented. 
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2.7.2 Reaction mixture for Apa 1 (may be made as a master mix). 
Per sample: 
distilled water 
10 X reaction buffer 
20U/JlI of Apa 1 
Then add 10JlI of PCR product and incubate at 37°C for 2 hours. 
4JlI of bromophenol blue was added directly to the digestion reaction and the total 
volume of 24JlI was loaded onto a 3%, gel with ethidium bromide staining. Positive 
control (provided by AE Harding) was run with the samples. 
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2.7.3 Reaction mixture for BstEIl (may be made as a master mix). 
Per sample: 
distilled water 
10 X reaction buffer 
10U/IlI of BstE11 
Then add 71-11 of PCR product and incubate at 60°C for 2 hours. The samples 
were then loaded onto a 3% agarose, 1 % NuSieve gel with ethidium bromide 
staining and electrophoresed. Digestion products were visualised using UV-light. 
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2.7.4 Restriction analysis to detect the glucokinase missense mutation 
Gly299 ~Arg. 
1 Jlg of genomic DNA was amplified by PCR using the primers: 
8c 
8d 
5' TCC CGG CTI CCA CCT GCA TGA 3' 
5' GTG GAA GAG CAG GTI TIC GTC 3' 
and cycling conditions of: 
Initial denaturation 96°C 3mins 
35 cycles of 94°C 15secs 
60°C 15secs 
72°C 20secs 
Final extension 72°C 10mins 
The product was 159 bp. After confirming amplification, 10JlI was digested with 
10Units of Hha 1 (or Cfo1) for 2 hours at 37°C. Fragments were resolved on a 2% 
agarose gel with ethidium bromide staining. 
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2.7.5 Restriction analysis to detect the mitochondrial DNA mutation of 
tRNA(LeuUuR) at position 3243bp. 
1 Jlg of genomic DNA was amplified by PCR using the primers: 
MITFS 
MITRS 
5' AAG GTT CGT TTG TTC AAC GA 3' 
5' AGC GAA GGG TTG TAG TAG CC 3' 
and the cycling conditions of: 
Initial denaturation 96°C 4mins 
30 cycles of 93°C 30secs 
52°C 30secs 
72°C 40secs 
Final extension 72°C 10mins 
The product was 428bp. After confirming amplification, 10JlI was digested with 
20Units of Apa1 for 2 hours at 37°C. Fragments were resolved on a 3% agarose 
gel with ethidium bromide staining. Presence of the mutation produces restriction 
fragments of 315bp and 113bp. 
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2.7.6 Restriction analysis to detect the point mutation Gly4°~Ser in the 
glucagon receptor gene. 
1 ~g of genomic DNA was amplified by PCR using the primers: 
FS 5' TGT CTG GTT GCT TGT GCA TG 3' 
RS 5' GM GAG MC TCA GGA AGT GC 3' 
and the following cycling conditions: 
Initial denaturation 94°C 5 mins 
32 cycles of 94°C 90 secs 
55°C 1 min 
72°C 30 secs 
Final extension 72°C 10 mins 
The product was 196bp. After confirming amplification, 5~1 was digested with SU 
of BstEIl at 60°C for 2 hours. Fragments were resolved on a 3% agarose, 1 % 
NuSieve gel with ethidium bromide staining. Digestion product was visualised 
using UV-light. Absence of the mutation results in digested fragments of 1 08bp 
and 88bp. Presence of the mutation removes a cutting site. The heterozygous 
mutation results in fragments of 196bp, 108bp and 88bp being visualised. 
70 
2.8 MUTATION SCREENING USING SINGLE-STRANDED CONFORMATIONAL 
POL YMORPHISMS (SSCP). 
2.8.1 Introduction. 
Screening for mutations prior to sequencing can reduce the time and costs of 
identifying mutations. This technique detects mutations as single-stranded 
conformational polymorphisms, with the possibility of distinguishing a single base 
change. 
In non-denaturing conditions single-stranded DNA has a folded secondary 
structure (conformation) which is determined by intramolecular interactions and 
therefore its amino acid sequence (primary structure). When electrophoresed on 
a non-denaturing polyacrylamide gel, the single-stranded DNA will have a specific 
mobility depending on this secondary structure. Any difference in the amino acid 
sequence of a DNA sample, due to a mutation or polymorphism, will be detected 
as a mobility shift and will produce a different band pattern when compared to the 
wild-type (Figure 2.8.1). 
The conformation of the single-stranded DNA may be altered by a number of 
conditions, these have to be optimised to detect the mutations: 
1 Properties of gel-pore size determined by percentage of 
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Figure 2.8. 1 Principles of mutation screening using the technique of single-stranded conformational 
polymorphism (SSCP) analysis. 
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polyacrylamide, ratio of acrylamide/bis (cross-linker), and temperature 
at which polymerisation is carried out, including temp. of reagents. 
2. Presence and percentage of glycerol; has a weak denaturing action which 
partially opens the folded structure so that more surface area is available 
for gel to "sense" conformational changes. 
3. Temperature at which electrophoresis is carried out. 
4. pH of buffer used to make gel. 
5. pH and Ionic strength of buffer system. 
Optimal conditions have been developed for each of the glucokinase exons 2-10 
(Chapter 5) 
2.8.2 Method. 
Amplify exon under investigation using relevant primers and PCR. 
Run PCR product on a 1.5% agarose gel to check amplification. 
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2.8.3 Preparation of polyacrylamide gels. 
For SSCP denatured samples are run on polyacrylamide gels at two different 
conditions, generally, 10% polyacrylamide gel with SOlo glycerol at 2SoC, and 10% 
polyacrylamide gel without glycerol at 4°C. 
Ensure distilled water is used for SSCP as chloride ions interfere with silver 
staining. 
For one gel the following volumes are used: 
4°C 2SoC 
10X TBE 3ml 3ml 
Distilled water 19.5ml 18ml 
SOlo glycerol 1.Sml 
Acrylamide/Bis 7.Sml 7.Sml 
TEMED 24JlI 24JlI 
2S% Ammonium Persulphate 190JlI 190JlI 
The gels are made using fresh 10X TBE and 2S% ammonium persulphate. 
The gels are poured at RT and allowed to polymerise for at least 2 hours prior to 
use. 
74 
Electrophoresis is carried out in 1 X TBE buffer. Prior to loading of samples the 
gel is run at 350V for 30 minutes. 
2.8.4 Sample preparation. 
SSCP loading dye: Bromophenol blue, xylene cyanol, and formamide. 
Formamide prevents the renaturation of the single strands of DNA after 
denaturation. 
Double stranded DNA (OS) is run with the samples to act as a marker. A positive 
control (PC) is also loaded onto each gel if available. The loading position of the 
OS and PC aids identification and orientation of the gel. 
Samples are prepared as follows in labelled PCR reaction tubes. 
Sample tubes: 16JlI dH20 + 2JlI SSCP dye + 2JlI PCR product 
PC tubes: 
OS tubes: 
The tubes are capped centrifuged for a few seconds at 4°C and then placed in the 
peR machine. 
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Samples are denatured at 95°C for 6 minutes. To prevent renaturation they are 
immediately placed on ice for 10 minutes. After this they are centrifuged for a few 
seconds at 40 C, and returned to ice. 
1 f.!1 of double-stranded DNA is then added to the DS tubes. 
The samples are then loaded onto the polyacrylamide gel using a duck-billed 
pipette tip. 
The gel is typically run at 350V for approximately 18 hours, but the voltage may 
be altered to vary the run-time and separation. 
2.8.5 Silver staining of gels. 
Bands are visualised by silver staining (BioRad). Clarity depends on the amount 
of sample loaded. Gel may have a dark background or be stained totally black 
due to chloride ions in the water used to make the solutions etc. The supplier's 
protocol is followed, except that excess oxidiser is removed with 4 x 5 minute 
washes with water 
SSCP is not infallible. May gain false positives or negatives, and have problems 
with reproducibility. 
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2.8.7 Mutation screening of the glucokinase gene using SSCP. 
PCR primers: 
Exon 2 
Exon 3 
Exon 4 
Exons 5&6a 
Exon 7 
Exon 8 
Exon gb 
Exon 10 
5' CCA GCC CGA CTG CTC CCA TCC 3' 
5' CTT CTG GAT GAG GAG CCG GTT 3' 
5' TAA TAT CCG GCT CAG TCA CC 3' 
5' CTG AGA TCC TGC ATG CCT TG 3' 
5' TAG CTT GGC TTG AGG CCG GTG 3' 
5' TGA AGG CAG AGT TCC TCT GG 3' 
5' GCA GCC ACG AGG CCT ATC TC 3' 
5' GAG CCT CGG CAG TCT GGA AG 3' 
5' AGT GCA GCT CTC GCT GAC AG 3' 
5' CAT CTG CCG CTG CAC CAG AG 3' 
82a 5' TGC CTG CTG ATG TAA TGG TCC 3' 
8b 5' TGA GAC CAA GTC TGC AGT GC 3' 
5' ACT GTC GGA GCG ACA CTC AG 3' 
5' CTT GGA GCT TGG GAA CCG CA 3' 
5' GTC GAC TGC GTG CAG GGC GC 3' 
5' TGT GGC ATC CTC CCT GCG CT 3' 
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aExons 5&6 are amplified together and then digested with Pst1 to obtain the two 
exons: 
bExon 9 is amplified and the 367 bp product is digested with Sph 1 to obtain 205 
and 162 bp fragments. 
Master mix for digestion with restriction endonuclease: 
H20 7fJ,1 
10X Buffer 2fJ,1 
Enzyme 1 fJ,1 
PCR Prod 10fJ,1 
Use sterilised pipette tips, tubes, covers and dH20. Ensure that enzyme and 
buffer are thawed. Thoroughly mix 10X buffer. Gently vortex master mix prior to 
use. 
Incubate at 37°C for 1.5 hours. 
When run on SSCP gel load twice as much sample as normal (ie 4fJ,1 sample, 2J .. d 
dye and 14fJ,1 dH20) 
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Amplify exon of interest using the above primers. 
Initial denaturation 96°C 4 mins 
35 cycles of 94°C 30 secs 
62°C 30 secs 
72°C 40 ssecs 
Final extension 72°C 10 mins 
PCR Master Mix for a 50f..l1 reaction vol. 
H2O 33f..l1 
10X buffer 8f..l1 
dNTP mix 8f..l1 
Primer 1 (25pM) 0.25f..l1 
Primer 2 (25pM) 0.25f..l1 
Taq 0.5f..l1 
SSCP- samples are run at two conditions (Chapter 5, Table 5.4). 
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2.9 SEPARATION OF PCR AMPLIFICATION PRODUCTS USING MAGNETIC 
DYNAL BEADS IN PREPARATION FOR DIRECT SEQUENCING. 
2.9.1 Requirements: 
1 Oynal Magnetic Particle Concentrator (MPC-E) from Dynal AS, Ltd., 
N-0112 Oslo, Norway. 
2 Oynalbeads M-2BO Streptavidin. 
3 TES (autoclaved): 10mM tris-HCI, 1 mM EDTA, 100mM NaCI. 
4 0.15M NaOH (made fresh daily; prepare 1 M stock in sterile water). 
5 Sequenase kit Version 2.0 United States Biochemical. 
2.9.2 Preparation of single-stranded template. 
1. PCR is performed in a 100lli reaction; one of the primers is 5' biotinylated. 
The PCR conditions have to be such that no non-specific products are 
produced. After confirmation of amplification, all the remaining volume is 
used in the subsequent procedures. 
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2. Resuspend Oynalbeads thoroughly prior to use. 
3. Take 50J!1 of beads per 20pmole of biotinylated primer and place into a 
0.5ml eppendorf tube. 
4. Resuspend required volume of Oynalbeads with 100J!1 of TES. Gently mix 
by pulling suspension up and down yellow tip with the pipette. No 
vortexing. 
5. Place the eppendorf tube into the Oynal MCP-E rack at RT with the hinge 
of the tube facing the back of the block. Leave for a minimum of 30 
seconds to allow the beads to be bound to the bottom of the tube. 
6. Carefully remove supernatant from the bottom of the tube and discard. 
Then remove tubes from MCP-E and place in a rack on the bench 
7. Repeat steps 4,5 and 6. 
8. Resuspend Oynalbeads by gentle repeated flushing with 100J!1 TES, using 
the pipette. 
9. Mix prewashed beads to all of the remaining PCR product. Mix gently 
using the pipette and leave in a rack on the bench for 5 minutes; give the 
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tubes an occasional gentle tap. This allows the double-stranded DNA to 
absorb to the beads. 
10. Place tube into MCP-E for 30 seconds. Remove supernatant and discard 
it. 
11. Add 100JlI of 0.15M NaOH to the tube, mix gently with the dsDNA and 
beads and leave on the bench for 5 minutes to allow denaturation of the 
DNA. The biotinylated strand will be retained on the beads and the non-
biotinylated strand will be in the solution. 
12. Place tube in MCP-E. Remove the supernatant containing the non-
biotinylated ssDNA and place in a new eppendorf tube. Take tube from 
MCP-E and place in rack on the bench. 
13. Add 1/10th volume of 3M Sodium Acetate pH5.6 and 2.5 volumes of ice-
cold ethanol. Place in freezer for 5 minutes. 
14. Remove tube from freezer and centrifuge. Wash with 80% ethanol, allow 
to dry. Resuspend pellet in 10-20JlI of distilled water. This non-
biotinylated strand is now ready for direct sequencing. Store at -20°C until 
required. 
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15. Resuspend the Dynalbeads (with the biotinylated ssDNA) in 100JlI TES; 
wash by gentle mixing using the tip and pipette. 
16. Place tube in the MCP-E, remove supernatant and discard. Place tube in 
rack on bench. 
17. Repeat steps 15 and 16 but use 100JlI of distilled water rather than TES. 
18. Resuspend Dynalbeads and biotinylated DNA in 20JlI of distilled water and 
leave at -20°C until required for sequencing. 
83 
2.10 SEQUENCING SINGLE-STRANDED DNA. 
2.10.1 General. 
Perform standard dideoxy sequencing protocol with USB Sequenase kit version 
2.0. Sequencing primers are preferably internal to the ones used for peR 
amplification, otherwise the same primers as those used for peR can be used. 
For ssDNA template generated with forward peR primer, use reverse internal 
sequencing primer. For ssDNA template generated with reverse peR primer, use 
forward internal primer. 
2.10.2 Annealing. 
Sequencing primer anneals to ssDNA template. 
Annealing reaction: 
template ssDNA 
5x reaction buffer 
sequencing primer (2pmol) 
distilled water 
TOTAL 
5JlI (max 7JlI, adjust volume of 
distilled water added). 
2JlI 
1 JlI 
2JlI (adjust in relation to template ssDNA) 
10JlI 
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1. Place components of annealing mixture into a sterile O.Sml eppendorf tube. 
Heat at 68°C in hot block and incubate for 2 minutes. 
2. Remove block from heater, and allow to coolon the bench to RT. 
3. Place tubes on ice until labelling is carried out. 
2.10.3 Preparation for the next steps. 
1. Thaw the following on ice: 
GTP labelling mix 
DTT 
a
35S dATP 
enzyme dilution buffer 
STOP solution 
ddNTP termination solutions 
2. Ensure the solutions are completely thawed before proceeding with the 
next steps. 
3. Prepare 4 tubes labelled with sample ID and G, A, T and C 
Add 2.SJ!1 of ddNTP termination solution to the respective tube. Prewarm 
at 37°C in hot block. 
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4. Dilute dGTP labelling mix to 1: 10 
5. Dilute Sequenase 1:8 with enzyme dilution buffer (use within 60 minutes of 
preparation) . 
2.10.4 Labelling. 
1. Prepare a master mix (containing OTT, dilute dGTP, a35S dATP and dilute 
Sequenase) according to the number of samples. 
Reaction mix per sample: 
DTT (0.1M) 1 ~I 
dGTP (diluted 1 :10) 2~1 
a35S dATP 0.5~1 
Sequenase enzyme (diluted 1 :8) 2~1 
TOTAL VOLUME 5.5~1 
2. Mix by gentle pipetting back and forth. Add reaction mixture to the tube 
containing the 1 O~I of template/primer complex. Incubate on bench at RT 
for exactly 3 minutes. 
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2.10.5 Chain termination reaction. 
1. When the labelling is complete, quickly and gently mix the solution. 
2. Aliquot into four 3.5ml volumes and add one into each of the four tubes 
containing the termination mix kept at 37°C, by carefully placing the 3.5ml 
volume as a drop onto the side of the eppendorf tube. 
3. When all four tubes have received an aliquot, remove them from the hot 
block, place in a mini-centrifuge and spin them for a couple of seconds. 
4. Remove the tubes from the centrifuge and replace them in the 37°C hot 
block. Incubate them for exactly 3 minutes. 
5. Remove the tubes from the hot block and place them in a mini-centrifuge. 
Add 4JlI of STOP solution to the side of each tube. Spin the tubes for a 
couple of seconds. 
6. The samples can now be stored at -20°C until required to run on the 
sequencing gel. 
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2.10.6 Sequencing gel. 
Use a 6% 7M urea denaturing gel. 
Require a pair of siliconised glass gel plates; one of the pair has a set of lugs. 
1. Mark side to be siliconised with a diamond scratcher. 
2. Wash plates with ethanol, then hot tap water, then distilled water. 
3. Place glass plates in flow hood with marked side facing upwards. Pour 
silicon (BOH UN No. 2810 - Merck Ltd., Prod. 33164: 
dimethyldichlorosilane solution. 2% in 1,1,1-) and wipe with a towel to 
evenly distribute over entire surface. 
4. Repeat once, then allow to dry, preferably in an oven at 110°C. 
5. Repeat step 3 when necessary, generally every 5-10 gels. 
6. Before every use, repeat step 2. 
7. With the siliconised surface facing upwards, place plastic spacers along 
both long sides of the glass plate which does not have the lugs. 
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8. Place the other glass plate on top with the siliconised side facing 
downwards. 
9. Seal sides and bottom of glass plates well with gel sealing tape (Sigma). 
10. Hold the sides of the glass plates with clamps. 
11. With lugged plate uppermost, incline the plates so that the open end with 
the lugs is higher than the bottom. 
2.10.7 Gel solution. 
Prepare the following as a stock solution: 
19: 1 acrylamide:bis 40% 
10 xTBE 
Urea 7M 
distilled water 
7Sml 
SOml 
210g (salt) 
up to SOOml 
Stir until dissolved; add a small amount of water at a time, ensuring the total 
volume of the solution does not exceed SOOml. Store at 4°C until required. 
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To prepare gel: 
1. Take 40ml of stock solution and add the following: 
10% ammonium persulphate 
TEMED 
Stir well. Solution will begin to set rather quickly. 
400lli 
30111 
2. Take up 30ml in a syringe and pour into one corner between the gel plates. 
Lift plates to allow gel solution to flow between the plates, down one side 
and across the bottom. Continue to pour gently until all the volume 
between the glass plates is full, ensuring that no air bubbles are trapped. 
3. Place toothed comb into the gel at the top of the opening between the 
glass plates with the teeth facing upwards, push in to approximately 3-
Smm. Cover top of gel with a paper towel soaked with 1 X TBE, then clamp 
and allow gel to set. After complete polymerisation gel wrap in cling film 
and store at 4°C until required. 
2.10.8 Running of sequencing gel. 
1. Remove cling film and clamps from glass plates, and the adhesive tape 
from the bottom. 
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2. Gently remove comb and rinse comb and wells with 1 x TBE. Replace 
comb with the teeth facing inwards and just touching the gel surface. 
3. Place glass plates vertically in gel apparatus; the plate with the lugs facing 
the upper buffer tank. Put metal against the other glass plate and clamp in 
position. 
4. Fill buffer tanks with 1 X TBE. 
5. Pre-run gel for 30 minutes at 25W. 
6. Denature prepared samples in hot block at 85°C for 2 minutes. 
7. Turn off current to gel apparatus and wash wells with 1 X TBE to flush out 
urea which continuously floats from gel. 
8. Load 2.5 - 3 fll of denatured sample using a pipette and a duck-bill tip. 
Rinse tip with distilled water after loading each sample. 
9. Run gel at 25W for various periods of time to obtain adequate separation. 
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2.10.9 Preparing gel for exposure. 
1. Turn off current to gel. 
2. Drain buffer. 
3. Remove comb, clamps and metal plate. 
4. Place glass plates horizontally on towel-covered bench with lugged plate 
facing upwards. Remove adhesive tape. Slide spacers out. 
5. Slowly lift top glass plate off of gel. Gel should adhere to bottom plate. 
6. Place glass plate with the gel into a tank. Gently pour a solution of 10% 
methanol/ 10% acetic acid so that the gel is completely immersed. Gently 
agitate tank to loosen gel until it floats freely. Allow to fix for 20 minutes. 
7. Remove methanol/acid solution and carefully place a sheet of Whatman 
filter paper on top of gel. Squeeze out air bubbles. Cover loosely with 
paper towels to absorb excess fixative solution. 
8. With the glass plate facing upwards and the gel sandwiched in-between, 
place filter paper onto surface of gel dryer. Gently lift glass plate leaving 
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the gel adhered to the filter paper. 
9. Apply vacuum and dry at 60 - 80°C for 45 minutes. Dried gel will securely 
adhere to filter paper. 
10. Expose directly to Kodak film in cassette at RT for 4 days. 
11. Develop exposed film using automated processor. 
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2.10.10 SEQUENCING OF THE GLUCOKINASE GENE. 
Amplify exon of interest using primers external to those used for SSCP. One of 
the pair of external primers has 5' biotinylation to enable separation of the dsDNA 
into ssDNA using Oynalbeads. The original internal primers are then used as 
sequencing primers. 
PCR amplification: 
Initial denaturation 
35 cycles of 
Final extension 
4mins 
30secs 
62°C 3dsecs 
72°C 40secs 
6mins 
PCR Master Mix for a 100lli reaction volume: 
H2O 66111 
10X buffer 16111 
dNTP mix 16111 
Primer 1 (2SpM) O.SIlI 
Primer 2 (2SpM) O.SIlI 
Taq Polymerase 1 III 
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PCR primers: 
Exon 3 external 
Exon 3 internal 
Exon 8 external 
Exon 8 internal 
Exon 9 external 
Exon 9 internal 
5' CTT GTG CCT TCC CTC CTC CT 3' 
*8 5' TAG ACA GGT GGC ACC TCC CGT 3' 
b 5' TCC TCC TCT TTG TAA TAT CC 3' 
a 5' TAA TAT CCG GCT CAG TCA CC 3' 
5' CTG AGA TCC TGC ATG CCT TG 3' 
*8 
*8 
5' GGC TTC CAC CTG CAT GAG GG 3' 
5' GCCCTA GTT TCC CGT CCC TG 3' 
5' TGC CTG CTG ATG TAA TGG TCC 3' 
5' TGA GAC CAA GTC TGC AGT GC 3' 
5' TCC CTG GAG AAC GAG AGG CC 3' 
5' ACG AGA AGA GGA CTA CGA AAT 3' 
5' ACT GTC GGA GCG ACA CTC AG 3' 
5' CTT GGA GCT TGG GAA CCG CA 3' 
*8 indicates 5' biotinylation of primer. 
A second internal forward primer (b) was designed for exon 3 to overcome 
problems with the sequencing reaction found when using the original internal 
primer (a). 
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3.1 INTRODUCTION. 
Maturity onset diabetes of the young (MODy) is a subgroup of Type 2 diabetes 
that presents from the second decade and has an autosomal mode of inheritance 
(Tattersall 1974; Fajans 1989) which makes it ideal for linkage studies. Tight 
linkage of the glucokinase gene on chromosome 7p to Type 2 diabetes has been 
found in French and British pedigrees with MODY (Froguel et al 1992; Hattersley 
et al 1992b). These studies utilised the polymorphic microsatellite marker GCK1 
(Matsutani et al 1992). 
In a large multi-generation Oxford pedigree (BX) with 15 diabetic members, a 
peak LOD score of +4.60 was obtained at a recombination fraction (9) of zero. 
This suggested that a mutation in the glucokinase gene contributed to the 
diabetes phenotype in this pedigree. Subsequently a missense mutation in exon 
8 of the glucokinase gene (Gli99 ~ Arg) was identified and shown to segregate 
with diabetes in this pedigree (Stoffel et al 1992b). The effected members in 
Pedigree BX were diagnosed either when they were young (in pregnancy or on 
screening) or when they presented symptomatically in middle or old age; most of 
them were treated by diet alone. 
We investigated five well-characterised UK MODY pedigrees for linkage to the 
glucokinase gene, including a new multi-generation pedigree (EA) with members 
from Edinburgh and Australia, using the polymorphic microsatellite markers GCK1 
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and GCK2 (Matsutani et al 1992; Tanizawa et al ; Nishi 1992). Studies by the 
French suggested that 56% of MODY pedigrees had diabetes which was caused 
by defects in the glucokinase gene (Froguel et al 1993). 
3.2 AIMS. 
To establish whether in these five MODY pedigrees diabetes was linked to the 
glucokinase gene. Those in whom linkage was excluded could then be used in 
studies of other candidate genes. 
3.3 METHODS. 
3.3.1 Subjects. 
Five white Caucasian MODY pedigrees were studied (Figure 3.3.1), the probands 
reside in London (M), Oxford (A), Leicester (H), Norwich (N) and Edinburgh (EA). 
The clinical details are shown in Table 3.3.1. Pedigree M is one of the 3 families 
first described by Tattersall (Tattersall 1974). 
3.3.2 PCR analysis of GCK1 and GCK2. 
DNA was extracted from peripheral whole blood by standard phenol/chloroform 
methods (Maniatis et al 1982). Amplification of the two microsatellite 
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Figure 3.3.1 Maturity Onset Diabetes of the Young (MODy) Pedigrees. 
Pedigree M 
II 
III 
IV 
V 
Pedigree A Pedigree N 
I 
II 
ill II 
N III 
Pedigree H 
• 
II 
III 
IV 
Pedigree EA 
II 
III 
IV 
V 
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Key to pedigree trees. 
Roman numerals on the left indicate generation number and numbers above the 
symbol indicate the patient number with that generation. 
Symbols are: 
squares=males 
circles=fema les 
closed symbol=diabetes 
diagonal shading (or diagonal cross)=glucose intolerance 
open symbol=normoglycaemia 
central dot=not tested 
slash=dead. 
This convention will be used on subsequent pedigrees. 
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Table 3.3.1 Clinical characteristics of MODY patients in the 5 families and in subjects in pedigrees BX with a glucokinase 
missense mutation. 
At diagnosis Current status 
Pedigrees Gender Age Diet/OHA/ins Age BMI (kg/m2) Therapy 
M/F (years) (years) median diet/OHA/ins 
Median median (range) 
(range) (range) 
M 1/8 15(8-28) 6/-/3 29(8-60) 23(21-26) 4/5/- I 
A 4/3 17(6-37) 1/3/3 38(19-56) 23(22-29) 1/3/3 
N 2/2 19(15-20) 2/2/0 35(25-46) 21 (21-22) 2/2/0 
H 5/4 21 (11-50) 5/0/3 26(21-76) 24(23-27) 3/2/3 
EA 4/11 19(14-48) 6/4/4 47(29-60) 25(22-33) 0/9/5 I 
Total or 10128 20/9/13 23(21-33) 10/21/11 
Medians 19(6-50) 35(8-76) 
BX subjects 
with a GCK 7/11 21 (14-63) 16/1/1 41 (18-81) 24(18-39) 15/2/1 
mutation 
OHA = Oral hypoglycaemic agents; ins = insulin; HbA1c = Haemoglobin A1c; GCK = glucokinase . 
polymorph isms GCK1 and GCK2 was performed using the polymerase chain 
reaction (PCR). O.OSflmoles of primers, in SOfll reaction volumes containing 
0.2Sfl9 of DNA, 100fl9 of each dNTP, 10 mmol/l Tris-HCI (pH3.8), SOmmol/1 KCI, 
1.Smmol/l and 1.S Units of BioTaq DNA polymerase. The PCR involved initial 
denaturing at 9SoC for 3 minutes, then 40 cycles of denaturing at 94°C for 30 
seconds, annealing at SSoC for 20 seconds, and extension at 72°C for 20 seconds 
and a final extension of 72°C for 10 minutes. 6ul of PCR product was 
electrophoresed on an 8% polyacrylamide gel at 1 OOV for 18 hours to resolve the 
alleles which were detected by ethidium bromide staining. 
3.3.3 Linkage Analysis. 
Each family was considered separately and analysed using MLiNK from the 
LINKAGE group of programs (version S.1) assuming dominant inheritance 
(Lathrop et al 1984). LOD scores were calculated with a recombination fraction of 
e = 0 appropriate for a candidate gene. Liability classes were based on 
prevalence studies of diabetes in the population and in MODY subjects. 
Age related penetrance was modelled on the assumption of fasting plasma 
glucose screening to detect subclinical disease as 0.60 for <20 years, 0.80 for 21-
30 years, 0.90 for 31-40 years, 0.9S for 41-S0 years, and 0.99 for >SO years for 
heterozygosity and 1 for homozygosity at all ages (O'Rahilly et al 1988b). 
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As the clinical presentation in these families was similar to that for classical Type 
2 diabetes, phenocopy rates for each liability class were those of the prevalence 
of Type 2 diabetes in the UK; 0.0001, 0.001, 0.001, 0.005, and 0.03 respectively. 
Allele frequencies for GCK1 are taken as being 0.632, 0.092, 0.270 and 0.007 for 
z, z+2, z+4 and z+6 respectively; for GCK 2 they are taken as 0.336, 0.592, 
0.046, 0.007 and 0.019 for 1, 2, 3, 4 and 5 respectively. These allele frequencies 
were determined in a British Caucasian normoglycaemic control population (See 
Chapter 4). 
3.4 RESULTS. 
In the five pedigrees studied diabetes did not segregate with any particular allele 
of either genetic marker. The calculated LaO scores are shown in Tables 3.4.1 
and 3.4.2. Using GCK1 (Table 3.4.1), Pedigrees Hand EA were non-informative 
for this marker The other 3 pedigrees all had a LaO score less than -2.00 (8=0) 
which excludes linkage. The cumulative LaO score for all five pedigrees is 
-12.38 (8=0). In two pedigrees it was possible to exclude linkage 1 centimorgan 
from the marker. 
Using GCK2 (Table 3.4.2), Pedigree A was non-informative for this marker. 3 of 
the other 4 pedigrees had a LaO score less than -2.00 (8=0) which excludes 
linkage. In these three pedigrees it was possible to exclude linkage 1 centimorgan 
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Table 3.4.1 LOD scores between diabetes and the glucokinase locus GCK1. 
Recombination fraction (e 
0.0 0.01 0.05 0.1 0.2 0.3 0.4 
TOTAL -12.38 -7.55 -3.95 -2.25 -0.73 -0.19 -0.05 
Pedigree M -5.10 -2.97 -1.53 -0.89 -0.36 -0.15 -0.06 
Pedigree A -3.66 -2.32 -1.09 -0.58 -0.17 -0.01 0.03 
Pedigree N -2.37 -1.09 -0.45 -0.21 -0.04 0.01 0.01 
Pedigree H -0.64 -0.58 -0.41 -0.26 -0.10 -0.03 -0.01 
Pedigree EA -0.62 -0.60 -0.47 -0.30 -0.06 0.00 -0.02 
Table 3.4.2 LOD scores between diabetes and the glucokinase locus GCK2. 
Recombination fraction (e) 
0.0 0.01 0.05 0.1 0.2 0.3 0.4 
TOTAL -17.51 -12.40 -7.21 -4.86 -2.45 -1.03 -0.25 
Pedigree M -4.23 -3.25 -1.92 -1.29 -0.66 -0.32 -0.11 
Pedigree A 0.05 0.05 0.03 0.00 -0.04 -0.04 -0.02 
Pedigree N -2.56 -1.66 -0.92 -0.57 -0.23 -0.09 -0.02 
Pedigree H -1.76 -0.83 -0.23 0.00 0.16 0.17 0.12 
Pedigree EA -9.00 -6.70 -4.17 -3.01 -1.68 -0.76 -0.22 
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from the marker. In Pedigree H, although formal exclusion is not possible, the 
finding of a LOD score of -1.76 makes it very unlikely that glucokinase mutations 
result in diabetes in this pedigree. The cumulative LOD score for all five 
pedigrees was -17.51 (8=0). 
3.5 DISCUSSION. 
Diabetes was not found to be linked to the glucokinase microsatellite DNA 
polymorph isms in the five pedigrees we investigated, suggesting that the gene 
responsible for diabetes in these five pedigrees is not at, or close to, the 
glucokinase gene locus. We have only found linkage of glucokinase with 
diabetes in one pedigree (8X) (Hattersley et al 1992b) out of six MODY 
pedigrees. This finding contrasts with the report that glucokinase mutations can 
account for diabetes in 56% of French MODY pedigrees (Froguel et al 1993). In 
the UK only 12.5% (1/8) Caucasian MODY pedigrees have diabetes linked to the 
glucokinase gene (Hattersley et al 1992b, Dow et al 1994, this Chapter 3). These 
differences may reflect true differences between the two countries, or be due to 
ascertainment bias. 
The five pedigrees studied here have quite severe diabetes which requires 
treatment with oral hypoglycaemic agents (OHA) and insulin. This contrasts with 
the phenotype observed in subjects with glucokinase mutations, many of whom 
have impaired glucose tolerance rather than overt diabetes which tends to be diet 
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or tablet controlled, most members remain undiagnosed, except in female 
members who become pregnant, and the sub-clinical diabetes rarely progresses 
to associated complications (Hattersley et a11992b; Page et al 1995). 
The results of this study further highlight the heterogeneity of MODY. Diabetes in 
MODY pedigrees has been found to be linked to the ADA marker on chromosome 
20q (Bell et a11991), and glucokinase (Froguel et a11992; Hattersley et a11992b) 
and there is at least one more gene responsible for this subgroup of Type 2 
diabetes. The pedigrees studied here have since been investigated for linkage to 
ADA and other candidate genes which could regulate insulin secretion 
(hexokinase II) and f3-cell sensitivity to glucose (glucagon-like polypeptide-1 
receptor, and pituitary adenylate cyclase-activation polypeptide receptor) and 
linkage with these has been excluded (Zhang et al 1995). 
Linkage analysis in pedigrees is a powerful tool for examining the role of 
candidate genes in the aetiology of inherited diseases with a defined mode of 
transmission (Ott J 1985). Pedigrees with MODY are particularly useful as they 
have a clear autosomal dominant mode of inheritance, and an early age of onset 
which allows ascertainment of affected members over three generations 
(Tattersall et al 1975; Kobberling et al 1982; O'Rahilly et al 1988a). When 
performing linkage analysis, the parameters were chosen to take into account the 
complicating factors of high prevalence of Type 2 diabetes in the general 
population and the age-dependent penetrance of the MODY gene. 
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This linkage study has shown that defects in the glucokinase gene are an unusual 
cause of diabetes in British MODY pedigrees with symptomatic hyperglycaemia. 
The results further highlight the heterogeneity of MODY. There are at least three 
genes involved in MODY, but as yet only glucokinase has been identified. 
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4.1 INTRODUCTION. 
Tight linkage of diabetes with the glucokinase (GCI<) locus on chromosome 7p 
has been described in French and British Caucasian pedigrees with Maturity 
Onset Diabetes of the Young (MODy), a subtype of Type 2 diabetes (Froguel et al 
1992; Hattersley et al 1992b). Following these results a nonsense mutation 
(Vionnet et al 1992) and missense mutations (Stoffel et al 1992a & b) of the 
glucokinase gene were identified. The missense mutation identified in the British 
MODY pedigree (BX) has also been found in a late onset Caucasian Type 2 
diabetes pedigree (AX) (Stoffel 1992a). This suggests that mutations in the 
glucokinase gene could contribute to the development of classical Type 2 
diabetes. Positive association in American Blacks and Mauritian Creoles support 
this possibility (Chiu et al 1992 a & b). These studies showed an association 
between alleles of GCK1 and classical Type 2 diabetes. 
4.2 AIMS. 
We investigated well-characterised white UK Caucasian Type 2 diabetic subjects 
and normoglycaemic control subjects with two microsatellite polymorphisms at the 
glucokinase loci, GCK1 and GCK2, to assess the contribution of the glucokinase 
gene to Type 2 diabetes. We examined for linkage disequilibrium between the 
polymorphisms and for an association with diabetes. 
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4.3 SUBJECTS. 
The initial cohort comprised 95 unrelated UK white Caucasian Type 2 diabetic 
subjects from the Oxford clinic of the UK Prospective Diabetes Study, and 76 
normoglycaemic volunteer controls from the same geographical area and ethnic 
group as the diabetic subjects. The diabetic subjects were all diagnosed after the 
age of 40 years. The normoglycaemic control subjects were all older than 50 
years and had a fasting plasma glucose <5.5 mmol/I. An additional cohort of 56 
identically defined Caucasian Type 2 diabetic subjects was examined at the 
GCK2 microsatellite polymorphism only. 
4.4 METHODS. 
4.4.1 PCR Analysis of the Microsatellite Polymorphisms GCK1 and GCK2. 
DNA was extracted from peripheral whole blood using standard phenol/chloroform 
methods (Maniatis et al 1982). The two microsatellite polymorph isms (Matsutani 
et al 1992; Froguel 1992; Tanizawa et al ; Nishi et al 1992) were amplified using 
the polymerase chain reaction (PCR). This was performed with 0.05 /.1moles of 
the primers in 50~1 reaction volumes containing 0.25/.1g DNA, 100/.1g of each 
dNTP, 10 mmol/I Tris-HCI (pH3.8), 50 mmol/I KCI, 1.5 mmol/I MgCb and 1.5 units 
of AmpliTaq DNA polymerase. The PCR involved initial denaturing at 95°C for 3 
minutes, then 40 cycles of denaturing at 94°C for 3 seconds, annealing at 55°C 
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for 20 seconds, and extension at 72°C for 20 seconds and a final extension of 
72°C for 10 minutes. 
Resolution of alleles was carried out by electrophoresing product on 20cm 8% 
polyacrylamide gels. Bands were detected by ethidium bromide staining, avoiding 
the need for radioactivity. Four alleles were identified for GCK1; z, z+2, z+4, z+6, 
where z is the commonest allele 195 bp long. Five alleles were identified for 
GCK2; 1, 2, 3, 4 and 5, which were 141, 139, 137, 135 and 129 bp long 
respectively. Haplotypes were constructed using the genotyping at the separate 
polymorph isms; this was possible when a subject was homozygous at one, or both 
of the marker loci. 
4.4.2 Statistical Analysis. 
To assess the relationship between the two polymorphisms, linkage disequilibrium 
between alleles was sought by comparing the frequency of the haplotypes with 
that expected from allelic frequencies, assuming no linkage disequilibrium. 
o was calculated as a measure of disequilibrium between two alleles at 2 
separate loci. When there were more than two alleles at a locus, 0 was 
calculated using the formula (Weir 1990): 
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where: 
Duv= is the disequilibrium constant between allele u at polymorphism 1 
and allele v at polymorphism 2. 
puv is the observed haplotype frequency with allele u at polymorphism 1 
and allele v at polymorphism 2 
Pu and Pv are the frequencies of alleles u and v respectively. 
To assess whether the disequilibrium between the two alleles significantly differed 
from zero the following value was used: 
which is asymptotically distributed as a X2 with one degree of freedom under the 
null hypothesis of D = 0 (Weir 1990). 
The allelic and haplotype frequencies in the Type 2 diabetic and non-diabetic 
control subjects was compared using the X2 test. In the analysis the overall 
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distribution of allelic frequencies, alleles with an expected frequency of 5 or less 
were pooled. When using X2 test to assess individual allelic frequencies and 
linkage disequilibrium between alleles a Bonferroni correction was made for 
multiple analyses. 
4.5 RESULTS. 
All the subjects were unambiguously assigned with each of the microsatellite 
polymorphisms investigated. 4 alleles were observed for the GCK1 
polymorphism, and 5 at GCK2. The heterozygote frequency in the normal 
population was 0.50 for GCK1, 0.66 for GCK2, and 0.80 for both polymorph isms 
combined. It was possible to infer unambiguous haplotypes with both markers in 
54 of the 76 normoglycaemic control subjects and 80 of the Type 2 diabetic 
subjects. 
4.5.1 Linkage Disequilibrium Between Polymorphisms in Normoglycaemic 
Control Subjects. 
Table 4.5.1 shows the results of linkage disequilibrium between polymorphisms in 
normoglycaemic control subjects. Allele z of the GCK1 polymorphism was 
positively associated with allele 1 of the GCK2 polymorphism (0 = 0.050, X2 = 
5.78, p<0.02) and negatively associated with the allele 2 (0 = 0.046, X2 = 4.917, 
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Table 4.5.1. Linkage disequilibrium between glucokinase microsatellite 
polymorphisms GCK1 and GCK2. 
Haplotype Observed 
frequency Expected 
in controls frequency 
GCK1 GCK2 (n=108) in controls D X2 
Z 1 0.269 (29) 0.219 0.050 5.786 a 
z 2 0.417 (45) 0.463 -0.046 4.917 b 
z 5 0.009 (1 ) 0.013 -0.004 0.383 
z+2 1 0.019 (2) 0.029 -0.010 0.655 
z+2 2 0.074 (8) 0.062 0.012 0.842 
z+4 1 0.028 (3) 0.067 -0.039 4.595 a 
z+4 2 0.176(19) 0.142 0.034 3.337 
z+4 5 0.009 (1 ) 0.004 -0.005 0.981 
Linkage disequilibrium between glucokinase polymorphisms GCK1 and GCK2 was assessed by 
the disequilibrium coefficient (D) in 54 normoglycaemic control subjects (108 chromosomes). The 
number of chromosomes in VIklich the haplotypes were observed are shown in parentheses. 
Expected frequencies were calculated from the allele frequencies assuming no linkage 
disequilibrium Statistical analysis by X2 is as described in the text a p<0.02, b p<0.05. When 
multiple analyses were corrected for there was no linkage disequilibrium. 
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p<0.05). There was a negative association between the z+4 and allele 1 
(D = -0.039, X2 = 4.595, p<0.05). However, with the Bonferroni correction for 
multiple comparisons (n=8) none of these associations remained statistically 
significant. 
4.5.2 Analysis of Haplotype and Allelic Frequencies in Normoglycaemic 
Control and Diabetic Subjects. 
Tables 4.5.2.1 and 4.5.2.2 show the results of allele and haplotype frequencies in 
the normoglycaemic control subjects and the initial cohort of diabetic subjects. 
There was no significant differences in the overall and individual frequencies of 
the alleles of the GCK polymorphism (z, z+4 and others X2 = 1.01, D.F. = 2, P 
=1>0.05) or the combined haplotypes (X2 = 4.65, D.F. = 4, P =1>0.1). At GCK2 
there was no significant difference in the overall distribution of allele frequencies 
(1,2 and others X2 = 5.72, D.F. =2, P = 0.057). Allele 1 was less frequent in the 
diabetic subjects than the normoglycaemic control subjects (22% vs 34%)(1 vs 
non 1 X2 = 7.934, D.F. = 1, p<0.02) and the 2 allele more frequent (70% vs 59%) 
(2 vs non 2 X2 = 4.785, D.F. = 1, p<0.05), but neither of these remained significant 
when multiple analyses (n=5) were taken into account. 
To assess whether there was a weak association at GCK2 which did not reach 
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significance due to the number of subjects studied, a second cohort of 56 Type 2 
diabetic subjects were typed for GCK2. When all 151 Type 2 diabetic subjects 
typed for GCK2 were analysed the allelic frequency distribution (Table 4.5.1.1) 
was similar to that found in the controls (1,2 and others X2 = 3.63, D.F. = 2, 
p=I>0.1). No significant difference was seen in the individual allele frequency of 
this expanded cohort even without correction for multiple analyses (1 vs non 1 X2 
= 3.530, D.F. = 1, p>0.05; 2 vs non 2 X2 = 3.081, D.F. =1, p>0.05). 
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Table 4.5.2.1 Allelic frequencies in diabetic and normoglycaemic control subjects 
for glucokinase microsatellite polymorph isms GCK1 and GCK2. 
Frequency in Frequency in Frequency in 
normoglycaemic initial diabetic expanded diabetic 
Allele controls (n=152) cohort (n=190) cohort (n=302) 
GCK1 
z 0.632 (96) 0.653 (124) 
z+2 0.092 (14) 0.063 (12) 
z+4 0.270 (41) 0.284 (54) 
z+6 0.007 (1 ) 0.000 (0) 
GCK2 
1 0.336 (51) 0.221 (42)a 0.252 (76) 
2 0.592 (90) 0.705 (134)b 0.675 (204) 
3 0.046 (7) 0.042 (8) 0.046 (14) 
4 0.007 (1 ) 0.010 (3) 0.010 (3) 
5 0.019 (3) 0.017 (5) 0.017 (5) 
.. The number of each allele observed are sho\NJ11n parentheses. Statistical analysIs by the 'X 2 
showed no significant difference in the overall distribution of allele frequencies in the diabetic 
subjects (initial and expanded cohorts) compared with the normoglycaemic control subjects at 
GCK1 and GCK2. Analysing the individual allele, significant differences were only seen between 
the initial diabetic cohort and the normoglycaemic controls: a p<O.02; b p<O.OS. These were not 
significant when they were corrected for multiple analyses. 
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Table 4.5.2.2 Comparison of glucokinase haplotype frequencies in 
normoglycaemic control and diabetic subjects. 
Haplotype Observed frequency Observed frequency 
in normoglycaemic in diabetic subjects 
GCK1 GCK2 controls (n=108) (n=160) 
z 1 0.269 (29) 0.194 (31) 
z 2 0.417 (45) 0.469 (75) 
z 3 0.000 (0) 0.019 (3) 
z 4 0.000 (0) 0.006 (1 ) 
z 5 0.009 (1 ) 0.006 (1 ) 
z+2 1 0.019 (2) 0.000 (0) 
z+2 2 0.074 (8) 0.037 (6) 
z+4 1 0.028 (3) 0.019 (3) 
z+4 2 0.176 (19) 0.231 (37) 
z+4 3 0.000 (0) 0.019 (3) 
z+4 5 0.009 (1 ) 0.000 (0) 
The number of chromosomes with the individual haplotypes are ShOWl in parentheses. Statistical 
analysis by the X2 test showed no significant differences in the overall, or individual haplotype 
frequencies. 
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4.6 DISCUSSION. 
We have examined two microsatellite polymorph isms (GCK1 and GCK2) at the 
glucokinase locus and have found no association with Type 2 diabetes in white 
UK Caucasian subjects. Use of more than one marker enabled us to define 
haplotypes which increases the power of population association studies and 
allows linkage disequilibrium between the alleles of the two markers to be 
assessed. Haplotypes increases the likelihood of finding linkage disequilibrium 
with a common mutation and have been applied to beta-thalassaemia (Orkin et al 
1982), cystic fibrosis (Estivill 1987), and phenylketonuria (Dilella 1987). 
In our normoglycaemic population, the linkage disequilibrium between the two 
markers was not significant when multiple comparisons were taken into account. 
This may reflect the sample size, rather than the absence of disequilibrium 
between these two polymorph isms which are approximately 50 kb apart. We only 
analysed haplotypes where they could be unambiguously assigned. Any bias 
from the exclusion of double heterozygotes is likely to be small as only 21 % of 
subjects could not be assigned a haplotype. Using both polymorph isms combined 
increases the heterozygosity rate to 80%, rather than 50% and 60% for GCK1 and 
GCK2 respectively. 
In this study no association was found with diabetes at GCK1, GCK2, or their 
combined haplotypes in the initial analysis of 95 Type 2 diabetic subjects and 76 
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normoglycaemic controls. The association with allele 2 of GCK2 was not 
significant when corrected for multiple analyses. To assess whether there was a 
weak association at GCK2 which had not reached significance due to the 
moderate number of subjects studied we typed a further 56 diabetic subjects at 
this polymorphism. In this second cohort and the total group of 151 diabetic 
subjects no significant association was seen. The analysis of a second 
independent cohort has been recommended prior to publication of positive 
association results to reduce the possibility of a positive association occurring by 
chance alone (Peto 1988). 
We have not confirmed the previous population associations seen with GCK1 in 
American Blacks and Mauritian Creoles in UK Caucasians. Our results indicate 
that a single mutation in the glucokinase locus is not a common cause of Type 2 
diabetes in our Caucasian population. 
As with all population association studies the data should be interpreted 
cautiously. An infrequent mutation that was in linkage disequilibrium with GCK1 
and GCK2 might be present but would not be detected due to the statistical 
power. The sample size we used would detect an association with 80% power if 
30% of Type 2 diabetic patients had a highly penetrant dominant mutation in tight 
linkage disequilibrium with a marker allele with a frequency of 0.1 (Cox et al 
1989). The statistical power of our study is sufficient to detect an association with 
a common mutation such as that found in 70% of cystic fibrosis (Karem 1990). 
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Our findings do not exclude the possibility that several different mutations of 
glucokinase might contribute to diabetes in a small proportion of Type 2 subjects. 
Linkage studies in Caucasian pedigrees with several affected members (Cook et 
al 1992; Dow et al 1994) support the conclusion that mutations in the glucokinase 
gene are unlikely to be common; weakly positive LOD scores were found in only 
2 of 12 pedigrees (Cook et al 1992), whereas 56% of MODY pedigrees are linked 
(Froguel et al 1993). 
A population association study in a Welsh Caucasian population (Tanizawa et al 
1993), linkage analysis of Caucasian Type 2 diabetic pedigrees (Cook et al 1992; 
Dow et al 1994), and mutation screening of the glucokinase gene (Chapter 6; MG 
Warren-Perry unpublished 1994) support our findings that one major mutation in 
or near the glucokinase gene is not a major cause of Type 2 diabetes in the UK 
Caucasian population. Over 20 different glucokinase mutations have been 
identified which cause diabetes, the majority of which are found in exons 7 and 8 
(Gidh-Jain et al 1992, Froguel et al 1993 & StCharles et al 1994). 
Positive population associations of diabetes with the microsatellite polymorphisms 
have been reported in American Blacks, Mauritian Creoles, Dravidian Indians, 
Japanese and Finns (Chiu et al 1992a & b; Noda et al 1993; McCarthy et al 1993 
& 1994a). It is possible that there is a common mutation within these ethnic 
groups. McCarthy et al and Noda et al point out the phenotypic similarity between 
Type 2 diabetes in Dravidian Indians and Japanese and subjects with a 
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glucokinase mutation. The positive population associations are not supported by 
SSCP analysis in American Blacks, Dravidian Indians, Japanese or Finns. No 
pathogenic mutations have been found in exons 2-10 of the glucokinase gene in 
these populations (Chiu et al 1993; Nishi et al 1994; McCarthy et al 1994b). 
There is the possibility that there is a pathogenic mutation in the promoter region 
of the gene, or in an intron at a splice-donor site that results in diabetes in these 
populations. Some data supports a role for a promoter polymorphism (Stone et al 
1994), but this is not clear. A mutation in the promoter region would be likely to 
affect the expression of the gene. Genetic admixture is the most common reason 
for false positive associations and might explain the results in these groups. This 
can occur even when every effort is made to match diabetics and controls. The 
best example of this is seen in the Nauruan population in which the European 
HLA component reduces the susceptibility of diabetes (Serjeantson et al 1983). 
There appears to be a number of potential problems with genetic heterogeneity in 
the Mauritian study The Mauritian Indians are form several areas of the Indian 
sub-continent, they were predominantly Hindu (80010) and a proportion of Muslims 
(13%); no breakdown was given between the diabetic subjects and controls and 
whether they were matched for religion. There will be differences in ethnic origin 
between the subjects, although Mauritius is not quite like India where strict 
segregation occurs between the religious and class groups, some segregation will 
have occurred. The Creoles are of African and Malagasy ancestry with various 
amounts of European and to a lesser extent Indian admixture. The authors did 
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refer to Serjeantson and his studies of Nauruans. No differences in the HLA 
alleles were found between the Type 2 diabetic subjects and controls in this 
study. As there was no association found in the Indians, the authors suggested 
that the Indians are not contributing genetic factors to the Creoles positive 
association, and that it was more likely to be due to the Black African and 
European Caucasian components. The Black African component was 
predominantly from Madagascar and French African colonies and may not itself 
be homogeneous. The contribution of European Caucasian components to the 
Creole positive association was not supported by the negative population 
association studies in two UK populations, although these two populations were 
both Northern European (Tanizawa et al 1993; this Chapter, 4) 
An investigation in Black Americans (Chiu et al 1992b) found the z+4 allele of 
GCK1 to be an independent risk factor for diabetes. This result was not 
supported by SSCP screening of 60 random Black Americans from this study to 
detect variants in subjects with z+4 and non-Z+4 alleles (Chiu et al 1993). A 
major investigation into the contribution of glucokinase gene mutations to Type 2 
diabetes in Dravidians (South Indian) has been conducted which utilised both 
population association and linkage studies (McCarthy et al 1993). Significant 
differences in allele frequencies at GCK1 were found with an increase in the z 
allele and decrease of the z+2 allele. No linkage of the glucokinase gene to Type 
2 diabetes was found; this along with the positive association suggests a minor 
role for a single mutation in the glucokinase gene as a cause of Type 2 diabetes 
123 
in this population. An association has been shown with the z+4 allele of GCK1 in 
a Japanese population (Noda et al 1993). A missense mutation of GCK has been 
identified in Japanese late-onset Type 2 diabetic pedigrees which would seem to 
support this (Katagiri et al 1992; Shimada et al 1993). A larger study of the 
contribution of glucokinase to Type 2 diabetes in Japanese subjects found no 
association of GCK alleles and haplotypes with diabetes (Nishi et al 1994). In 
addition, mutation screening of exons 2-10 failed to identify any mutations, and 
the polymorph isms detected did not associate with Type 2 diabetes. These 
results suggest that mutations of the glucokinase gene are not a major cause of 
late-onset Type 2 diabetes in Japanese subjects. 
A strong association has been found between alleles at GCK1 and glucose 
intolerance and diabetes in elderly Finnish men (McCarthy et al 1994a), but this 
has not been supported by SSCP screening (McCarthy et al 1994b). A previous 
study in this cohort found differences in HLA haplotypes between diabetic and 
control subjects and concluded that H LA is a major genetic determinant of Type 2 
diabetes (Tuomi lehto-Wolf et al 1993). Alternatively, these results could suggest 
that genetic admixture was present in this population and could explain the 
positive population association and negative mutation screening. 
We have found no association of the glucokinase locus with Type 2 diabetes in a 
UK Caucasian population. This suggests that one major mutation in or near the 
glucokinase gene is not a major cause of Type 2 diabetes in the UK Caucasian 
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population. These results are supported by linkage analysis of UK Caucasian 
Type 2 diabetic pedigrees and mutation screening of the glucokinase gene. 
Reviewing the published population association investigations of the contribution 
of glucokinase gene mutations to Type 2 diabetes reveal the problems involved in 
conducting such studies. The results need to be analysed cautiously, and used in 
conjunction with linkage studies and mutation screening to gain a clearer and 
more accurate picture. 
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CHAPTER 5 
DEVELOPMENT OF SSCP TO ENABLE MUTATION SCREENING 
OF THE GLUCOKINASE GENE 
5.1 INTRODUCTION 
5.2 AIMS 
5.3 METHODS 
5.4 RESULTS 
5.5 DISCUSSION 
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5.1 INTRODUCTION. 
Mutations in the glucokinase gene are a cause of diabetes in subjects with 
MODY, a subgroup of Type 2 diabetes. We intended to screen subjects with 
gestational diabetes, particularly those who went on to develop Type 2 diabetes, 
for mutations in the glucokinase gene and therefore required a simple, rapid and 
reproducible method. SSCP analysis detects base changes in the DNA sequence 
as differences in electrophoretic mobility when compared to "wild-type" (Orita et al 
1989). SSCP had been shown to be effective in detecting glucokinase mutations 
in French, British and Japanese pedigrees (Vionnet et al 1992; Stoffel et al 
1992b; Katagiri et al 1992), so we decided to use this method. 
5.2 AIMS. 
To develop single-stranded conformational polymorphisms analysis to screen for 
mutations of the glucokinase gene in at-risk populations of subjects such as 
gestational diabetic subjects. This method needed to be sensitive, detecting as 
many mutations as possible. 
5.3 METHODS. 
Individual exons, and at least 30 bases of the intron, were amplified using primers 
modified from those previously published (Stoffel et al 1992a; Chiu et al 1993) 
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and conditions described in Chapter 2; 2.8.1-2.8.7. Following PCR amplification, 
samples were heat denatured to form single-stranded DNA and electrophoresed 
under different conditions. Gels were silver-stained to visualise the different 
conformers (BioRad). The percentage of polyacrylamide, ratio of acrylamide:bis, 
amount of glycerol, and temperature at which electrophoresis was carried out 
were altered to optimise the resolution of conformers and obtain reproducibility. 
We used a heater-cooler system to control the temperature (Bettatech, UK) 
To ensure that the SSCP conditions were able to detect a point mutation, positive 
controls were used which were known to contain a single point mutation or 
polymorphism. A single positive control for exons 2 - 10 were kindly supplied by 
Dr Philippe Froguel. In addition, the Gli99 ~Arg missense mutation in exon 8 of 
the glucokinase gene (Stoffel et al 1992b) was used. 
We initially developed conditions to screen exon 8, as we had two positive 
controls. We then applied these conditions with minor modifications to the other 
exons. Gestational diabetic subjects, normoglycaemic subjects and positive 
controls were run. 
5.4 RESULTS. 
The Gli99 ~Arg missense mutation in exon 8 had been detected within our 
department in Pedigrees BX and AX using SSCP (Stoffel et al 1992b). We 
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initially tried to replicate these methods for this exon, using sample from members 
of Pedigree BX who possessed the exon 8 mutation as a positive control. We 
failed to reproduce the results using the same conditions and therefore had to 
develop our own conditions for SSCP and expand them to include all the exons 
from 2-10. 
By altering the SSCP conditions, with regard to the polyacrylamide gel and 
electrophoresis parameters, the conformation of the single-stranded DNA may be 
altered; these conditions are optimised to detect the mutations. 
Figures 5.4.1-3 show 3 SSCP gels for exon 8 of the glucokinase gene. The band 
patterns for each gel were produced by different conditions. This shows how 
altering the conditions can affect the conformation of the ssDNA and produce 
changes in the electrophoretic mobility of a sample. 
Figure 5.4.1. 6% polyacrylamide without glycerol, run at 25°C. The positive 
controls from Pedigree BX have the same band pattern as the normoglycaemic 
controls. The low and high bands are both singlets. The French positive controls 
have low and high doublet bands, and can therefore be distinguished from the 
other samples. 
Figure 5.4.2. 6% polyacrylamide with 5% glycerol, run at 25°C. These are the 
same conditions previously used by my colleagues to screen for the GI/99 ~Arg 
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missense mutation in members of Pedigree BX (Stoffel et al 1992b). The positive 
samples from this Pedigree are indistinguishable from the normoglycaemic 
controls. The French positive control possesses a low doublet, and unlike the 
previous conditions no high doublet. 
Figure 5.4.3. 10% polyacryalmide with 5% glycerol, run at 25°C. With these 
conditions each of the positive controls and the normoglycaemic control subjects 
could be distinguished. The positive sample from Pedigree BX possess a high 
doublet. The French positive controls have the low and high doublet previously 
seen in Figure 5.4.1. 
The positive controls were used to establish which gel conditions were suitable 
for mutation screening of each respective exon. They were run together under 
various SSCP gel conditions along with normoglycaemic controls. For each exon, 
we chose the gel conditions that enabled us to distinguish the positive control 
samples from the normoglycaemic samples (Table 5.4}.We were able to identify 
all of the positive control samples for exons 2-10. 
During method development an abnormal conformer in exon 8 of the glucokinase 
gene was detected in two samples (Figure 5.4.4). The positive control was not 
wholly reproducible at this time. After confirmation on 3 separate SSCP gels from 
the same product, the samples were sequenced. They were found to possess 
normal "wild-type" sequences (sequencing up to 16 clones). Reamplification 
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Figure 5.4.1 60/0 polyacrylamide gel without glycerol, run at 2SoC. 
F B N F 
F French positive control 
B Pedigree BX positive control 
N Normoglycaemic control 
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Figure 5.4.2 6% polyacrylamide gel with 5% glycerol , run at 25°C. 
F B N 
F French positive control 
B Pedigree BX positive control 
N Normoglycaemic control 
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Figure 5.4.3 10% polyacrylamide gel with 5% glycerol, run at 25°C. 
-
.'.~ .. -
, 
B F N 
F French positive control 
B Pedigree BX positive control 
N Normoglycaemic control 
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Figure 5.4.4 6% polyacrylamide gel with 5% glycerol, run at 25°C. 
B GA GA N G 
B Pedigree BX positive control 
GA Gestational diabetic subjects with abnormal band patterns 
N Normoglycaemic control 
G gestational diabetic subject 
The abnormal conformer was found to have been produced by normal 'wild-type' 
sequence. 
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Table 5.4 SSCP conditions used for mutation screening of exons 2-10 of the 
glucokinase gene. 
GCK exons Polyacrylamide gel Temperature Duration of 
conditions gel is run at. electrophoresis 
at3S0V 
2 10% without glycerol 4°C 18 hours 
100/0 without glycerol 2SoC 18 hours 
3 10 % without glycerol 4°C 18 hours 
10% without glycerol 20°C 18 hours 
4 10% without glycerol 4°C 18 hours 
1 0% without glycerol 2SoC 18 hours 
S&6 10% without glycerol 4°C 6 hours 
10% with 5°,4 glycerol 2SoC 6 hours 
7 10% without glycerol 4°C 18 hours 
10% without glycerol 1SoC 18 hours 
8 10% without glycerol 4°C 18 hours 
10% with 5% glycerol 2SoC 18 hours 
9 10% without glycerol 4°C 6 hours 
10% without glycerol 2SoC 6 hours 
10 10% without glycerol 4°C 18 hours 
10% without glycerol 2SoC 18 hours 
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from genomic DNA and SSCP did not continue to show abnormal conformers. 
5.5 DISCUSSION. 
A method to screen for mutations in exons 2-10 of the glucokinase gene was 
developed using the technique of SSCP analysis and silver-staining thus negating 
the requirement for radioactivity. Although SSCP had been used by members of 
our department in a laboratory 3 miles away, when the conditions were 
transferred we were unable to detect the Glj99 ~Arg missense mutation in exon 8 
of the glucokinase gene. This shows that optimum conditions may vary between 
laboratories and technicians and has been reported by other workers (Elbein et 
ai, 1993a). 
The final protocol was found to be accurate and reproducible and could detect all 
of the positive controls we possessed. It was established that for each exon the 
conditions selected were able to detect single base changes in DNA sequence 
resulting in a polymorphism or mutation. There still remains the possibility that 
some conformers may be missed. Developmental work showed the importance of 
having DNA samples with known mutations and "wild-type" samples to act as 
quality controls to ensure that each gel resolves different conformers and that no 
problems have occurred with the equipment and parameters during 
electrophoresis. If appropriate controls are unavailable for the particular exon or 
gene being studied, it is preferable to run other controls of the same length with 
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the understanding that the conditions may not be optimal for the exons of interest. 
General conditions may by used to detect base changes and these can be further 
optimised to gain clearer gels for photography and publication. 
SSCP can detect between 80 - 95% of all single base changes with appropriate 
conditions (Orita et al 1989). Sheffield et al have investigated the sensitivity of 
SSCP in the detection of single-base substitutions (Sheffield et al 1990). They 
found that the resolution of single-stranded DNA is improved with a fragment size 
<200bp, with an optimum size of approximately 150bp. They found a reduction in 
the sensitivity as the size of the fragment increases. Results suggested that there 
was a minimum size limit to detection, this is probably due to the constraints 
placed on the ability of a small fragment to form stable secondary structures. The 
ability of a fragment to form stable conformers is also affected by the base 
sequence surrounding a base change. No significant differences were found for 
the detection of transitions (81 % ) or transversions (76%). The lowest detection 
rate for any class of mutations was for G to T transitions (57%), detected at a 
significantly lower rate than for all other mutations (79%). 
The explanation of the abnormal conformers in exon 8 seen during method 
development is uncertain, but may be due to errors in PCR amplification with Taq 
polymerase. Once SSCP conditions had been optimised, no abnormal 
conformers in the samples were detected in exon 8. This finding shows that false 
positives may occur because of the formation of more than one conformer for a 
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particular sequence and has been supported by other workers (Elbein et ai, 
1993a). 
Robust SSCP conditions were developed which had been proven to detect all of 
the known glucokinase mutations in our possession. This meant that we could 
progress to the screening of subjects for mutations in exons 2-10 of the 
glucokinase gene, and be confident of detecting the majority of single-base 
changes. 
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CHAPTER 6 
MUTATIONS IN THE GLUCOKINASE GENE CONTRIBUTE TO THE 
PATHOGENESIS OF GESTATIONAL DIABETES 
6.1 INTRODUCTION 
6.2 AIMS 
6.3 METHODS 
6.3.1 Subjects 
6.3.2 Mutation Screening 
6.3.3 Sequencing and RFLP analysis. 
6.4 RESULTS 
6.5 DISCUSSION 
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6.1 INTRODUCTION. 
We observed that subjects with glucokinase mutations often present with 
gestational diabetes. 7 of 11 parous women from two pedigrees (AX and BX) with 
a missense mutation in exon 8 of the glucokinase gene (Glj99 ~ Arg) were initially 
diagnosed with gestational diabetes (Hattersley et al 1992b; Stoffel et al 1992). 
Gestational diabetes has a similar clinical phenotype to subjects with MODY 
possessing a glucokinase mutation, in that they have an early age of onset, mild 
hyperglycaemia leading to symptomatic diabetes in later life, and tend to have a 
strong family history of diabetes (Froguel et al 1993; Page et al 1995). The 
frequency of glucokinase mutations in subjects with gestational diabetes is not 
known. 
6.2 AIMS. 
To investigate the prevalence of gestational diabetes caused by mutations in the 
glucokinase gene by screening subjects using the technique of single-stranded 
conformational polymorphism (SSCP) analysis. 
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6.3 METHODS. 
6.3.1 Subjects. 
50 unrelated Caucasian subjects from the Oxford region who had been 
diagnosed as having Gestational diabetes (GDM) were studied. Gestational 
diabetes was diagnosed on the basis of 2 abnormal oral glucose tolerance test 
(OGTT) values during pregnancy (28-34 weeks) and with hyperglycaemia (>5.5 
mmol/I) on follow up (mean 10 years) (MD Gillmer 1983). Subjects known to be 
members of pedigrees AX and BX were excluded from the study. The clinical 
characteristics of the subjects are shown in Table 6.3. 
6.3.2 Mutation screening. 
Blood samples from the 50 subjects were taken into EDTA and DNA extracted 
from whole blood using the standard phenol/chloroform method. Mutations in 
exons 2-10 of the glucokinase gene have been found to be a cause of 
hyperglycaemia. Mutation screening of these exons was carried out using the 
technique of single-stranded conformational polymorphism (SSCP) analysis (Orita 
et al 1989). PCR amplification of exons 2-10 and SSCP analysis was performed 
as described in Chapter 2; 2.8.1-2.8.7 and Chapter 6. Generally, 2JlI of peR 
product was run for 18 hours at 350V on 10°A, polyacrylamide gels under two 
conditions; with 5% glycerol at 25°C and without glycerol at 4°C. 
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Table 6.3 Clinical characteristics of the gestational diabetic subjects. 
GDM 
Number of subjects 50 
Fasting Plasma Glucose 6.8 +/- 1.6 
mean +/- sd, mmol/I. 
Age mean +/- sd, years. 37.0 +/-0.3 
8MI mean +/- sd, kg/m2 29.0 +/- 3.4 
Known family history of diabetes 70% 
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Amplified DNA from a normoglycaemic subject, and for each exon a subject 
known to possess a glucokinase mutation were run as negative and positive 
controls. Gels were visualised by silver staining (BioRad). 
6.3.3 Sequencing and RFLP analysis. 
Exons from subjects shown to have an abnormal band mobility were directly 
sequenced after isolating single-stranded DNA using biotinylated PCR primers 
and Dynalbeads (Dynal UK) (Chapter 2; 2.9-2.10.10). The previously 
characterised missense mutation (Glj99 ~ Arg) was confirmed by a specific PCR 
generated RFLP using the restriction endonuclease Hha1 (Stoffel et a11992b; 
Chapter 2,2.7.4). 
When a mutation was found, other members of the subject's family were obtained 
and tested for glucose tolerance, and the presence of the mutation by use of 
SSCP and the specific RFLP. Paternity was established using DNA finger-
printing and highly polymorphic markers (ICI Diagnostics). 
6.4 RESULTS. 
After screening 50 gestational diabetic subjects, abnormal band patterns were 
detected in 3 exons (Table 6.4). The results of the normoglycaemic subjects 
suggested that the abnormal band patterns seen for exons 3 and 9 are due to 
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Table 6.4 Location of abnormal conformers and the number of GDM subjects and 
Normals found to possess them. 
GDM Normals 
Exon 3 8/50 10/50 
Exon 8 3/50 0/100 
Exon 9 a 10/50 12/52 
b 2150 0/52 
Two abnormal conformers were identified in exon 9, here designated a and b. 
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polymorph isms. Direct sequencing of exons 3 and 9 has failed to identify a base 
change resulting in a mutation or polymorphism. 
In exon 8 we had already described a mutation in this exon in two pedigrees (AX 
and BX). 3 unrelated subjects had a similar abnormal band pattern mobility to 
members of Pedigrees AX and BX who possessed a glucokinase mutation (Figure 
6.4.1). This particular mutation can be detected as a restriction fragment length 
polymorphism (RFLP), as the presence of this mutation creates a cutting site for 
the restriction enzyme Hha1. Direct sequencing and the use of the RFLP 
confirmed that these 3 subjects had the Gli99 ~ Arg missense mutation found in 
Pedigrees AX and BX (Figures 6.4.2 and 6.4.3). This mutation in exon 8 has not 
been found to occur in 100 non-diabetic individuals screened using SSCP and the 
RFLP. 
We further investigated the families of these 3 gestational diabetic subjects by 
sampling available family members and studying family records. In two subjects 
one parent and at least one other relative had diabetes compatible with dominant 
inheritance. The mutation segregated with diabetes and glucose intolerance. In 
the third subject, neither parent had hyperglycaemia or diabetes. Subsequent 
testing showed that there was non-paternity, so the family could not be fully 
studied. 
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Figure 6.4.1 SSCP gel for Exon 8. 
B F N GP GP 
B Pedigree BX positive control 
F French positive control 
N Normoglycaemic negative control 
GP Gestational Diabetic subject with abnormal SSCP band pattern 
The gel shows a gestational diabetic subject possessing an abnormal band 
pattern for exon 8. 
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Figure 6.4.2 Sequence data for one of the gestational diabetic subjects 
found to possess an abnormal band pattern in exon 8. 
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Figure 6.4.3 RFLP for the exon 8 mutation Glj99 ~Arg. 
~ lS9bp 
~ 
B N GN GO 
B Pedigree BX positive control 
N Normoglycaemic negative control 
GN gestational diabetic with normal SSCP band pattern 
GO gestational diabetic with abnormal SSCP band pattern 
The RFLP confirmed that the gestational diabetic subject possessed the 
previously described GI199 ~Arg missense mutation. 
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6.5 DISCUSSION. 
This study shows that mutations in the glucokinase gene can contribute to the 
pathogenesis of gestational diabetes. On screening 50 subjects, we found that 3 
unrelated subjects possessed a missense mutation (Glj99 ~ Arg) in exon 8 of the 
glucokinase gene. This same mutation has been previously described in two 
pedigrees (AX and BX) (Stoffel et al 1992b). This mutation results in glucose 
intolerance: 27 of the 28 individuals possessing the mutation have a fasting 
plasma glucose greater than 6 mmol/I 
A model of human f3-cell glucokinase has been constructed based on the related 
yeast hexokinase B (Gidh-Jain et al 1993; R StCharles et al 1994). These two 
enzymes share 31 % identity and all known catalytic and glucose-binding residues 
are conserved in these enzymes. This model enables the assessment of the 
effect of mutations on the molecular mechanism of the glucokinase enzyme. The 
Glj99 residue is highly conserved between species and is located in the region of 
the molecule leading to the cleft of the active site (Figure 6.5). It has been 
predicted that the charge alteration associated with the glycine to arginine 
mutation alters the conformation and stability of the enzyme. 
Kinetic enzyme studies have been carried out in E. coli to discover how this gene 
mutation affects the function of the enzyme molecule (Gidh-Jain et al 
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Figure 6.5 Model of the glucokinase molecule. 
A ribbon drawing of the a-carbon backbone of glucokinase, based on the yeast 
hexokinase B structure in the open conformation. The position of the Glj99 -j-Arg 
is indicated (Gidh-Jain et al 1993). 
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1993). The results of this are given in Table 6.5. The Km for glucose showed no 
significant difference; Km for ATP remains the same. The missense mutation 
reduces the Vmax of the glucokinase molecule to approximately 1 % of the native 
form of the enzyme, thus its glucose phosphorylating activity is greatly reduced. 
This decrease in function effects insulin secretion from the f3-cell. The Glj99 ~ 
Arg mutation is heterozygous, one of the patient's alleles is normal and therefore 
only 50% of the glucokinase enzyme is abnormal. This is seen in other 
glucokinase mutations, a homozygous glucokinase mutation would have severe 
effects and would be incompatible with life. 
Meglasson and Matchinsky (1990) postulated that a decrease in glucokinase 
enzyme activity may result in a reduced insulin secretion in relation to blood 
glucose levels. They suggested that a mere 15% reduction in glucokinase activity 
might shift the set point for glucose induced insulin secretion from 5 to 6 mM. It is 
uncertain what the overall effect will be if 50% of the enzyme has greatly reduced 
activity. It is interesting that affected members from the MODY pedigree BX have 
an approximately 50% decrease in f3-cell function (Hattersley et al 1992b; Page et 
al 1995). This suggests an important regulatory role for glucokinase, and 
expression of the enzyme is unable to compensate for the mutation's inactivity. 
The mutant glucokinase enzyme probably does not interfere with the function of 
the normal enzyme, particularly as it is monomeric. The defect in glucose 
metabolism is probably due to a gene-dose effect; there is less normal-functioning 
enzyme present. No changes in DNA sequence were identified by 
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Table 6.5 Results of kinetic enzyme studies on glucokinase carried out in E. coli 
V max, U/mg Km Glucose, mM KmATP, mM 
Native liver GCK 
98 +/- 9 6.8 +/- 1.3 0.23 +/- 0.19 
isozyme 
Native p-cell GCK 
100 +/- 8 8.0 +/- 2.0 o. 15 +/- o. 18 
isozyme. 
Gli99~Arg 
approx.0.32 3.1 +/- 2.1 o. 15 +/- o. 1 0 
mutation 
approx. 1 % native 
No significant difference in the Km for glucose. Km for ATP remains the same. 
Reduction in the Vmax of the mutant glucokinase molecule to approximately 1 % of 
the native form (Gidh-Jain et al 1993). 
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direct sequencing for the abnormal conformers found in exons 3 and 9. There are 
a number of reasons for this occurring. The abnormal conformer may be due to a 
PCR artefact created by Taq polymerase error, the exon may not have been 
amplified with high fidelity. This seems unlikely as the SSCP appearance was 
consistent and reproducible. Alternatively the abnormal conformer may actually 
be another form of that for the normal allele. There may be problems with direct 
sequencing of certain abnormal conformers. It has been suggested that primer 
annealing error may occur resulting in preferential binding to the normal allele 
thus producing a signal for this alone (personal communication Dr Choudury, 
Institute of Molecular Medicine, Oxford). 
Dr Mark McCarthy has endeavoured to sequence the abnormal conformers he 
found in exon 3 on the Applied Biosystems (ABI) automatic sequencer using the 
Sequenase kit. He found that this was not a robust method and had problems 
with obtaining sequence data and reproducibility. He then used the alternative of 
Taq sequencing with the ABI. This is reported to be less sensitive at detecting 
heterozygous mutants. To date, he has not been able to identify any abnormal 
DNA sequences in the abnormal conformers he detected (personal 
communication). 
Other studies have now been published which have assessed the contribution of 
mutations in the glucokinase gene to gestational diabetes. All of these utilised 
SSCP to screen the subjects. Mutations have been found in Caucasians (Zouali 
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et al 1993; Stoffel et al 1993) and an Hispanic (Stoffel et al 1993), but not in 
African-Americans (Chiu et al 1993). The results suggest that 5-10% of 
gestational diabetes in Caucasians and Hispanics may be due to mutations in the 
glucokinase gene (Zouali et al 1993; Stoffel et al 1993; and this Chapter 6). 
The detection of the missense mutation in exon 8 of the glucokinase gene has 
clinical significance. All 24 subjects from Pedigrees AX and BX with this 
glucokinase mutation had mild hyperglycaemia which was diet or tablet controlled. 
Most were non-obese and would have a good prognosis, with little tendency to 
macrovascular complications (Hattersley et al 1992b; Page et al 1995). Subjects 
with a glucokinase mutation tend to need insulin during pregnancy (9/11), 
although they are otherwise diet or tablet controlled. 50% of the subjects' children 
are at-risk of possessing this mutation. In view of the good prognosis, it is 
doubtful whether screening them is justified, although it may provide "good" news 
for those with the mutation because of the relatively "mild" phenotype. It would be 
more feasible if rapid and accurate screening was possible. Individuals with the 
same mutation have been classified as having MODY, classical Type 2 diabetes 
or gestational diabetes depending on when they have been diagnosed. 
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7.1 INTRODUCTION. 
Work carried out in Oxford has focused on the role of the glucokinase gene in 
Type 2 diabetes. Our results have identified five probands from the Oxford district 
who possess the same missense mutation in exon 8 of the glucokinase gene. 
One of these individuals presented with maturity onset diabetes of the young 
(MODy), one presented with Type 2 diabetes, and three presented with 
gestational diabetes (GDM). The mutation we found was a missense mutation 
Glj99 ~Arg in exon 8; it is the only glucokinase mutation to be found in five 
probands. We suspected the role of a founder-effect in this area as a cause of 
this high prevalence. 
7.2 AIM. 
To assess whether the high prevalence of the Glj99 ~Arg glucokinase mutation in 
the Oxford district is due to a founder-effect. 
7.3 SUBJECTS. 
7.3.1 Screening of MODY pedigrees. 
Six large multi-generation pedigrees were investigated using the microsatellite 
marker GCK1 and GCK2 (Hattersley AT 1992b; Chapter 3). One of these 
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pedigrees, Pedigree BX (Figure 7.3.1) was found to have diabetes mellitus linked 
to the glucokinase gene. Mutation screening, using the technique of single-
stranded conformational polymorphism (SSCP) analysis was carried out. 
Subjects within Pedigree BX possessing the z+4 allele, which segregated with 
diabetes, produced an abnormal band pattern in exon 8, and sequencing 
identified the mutation to be a missense mutation resulting in Glj99 ~Arg. This 
mutation was found to be identifiable as an RFLP as it created a cutting site for 
the restriction endonuclease Hha1 (Stoffel 1992b). 
7.3.2 Screening of Type 2 diabetic patients. 
Colleagues screened 50 Type 2 diabetic subjects with diagnosis >40 years old for 
mutations in exons 7 and 8 using SSCP and RFLPs (Stoffel et al 1992b). Of 
these, one subject was found to possess the missense mutation in exon 8. 100 
non-diabetic subjects screened do not possess this mutation, further confirming 
that this mutation is the cause of diabetes. 
The Type 2 diabetic subject with the mutation is a member of a large multi-
generation pedigree, Pedigree AX (Figure 7.3.2). Pedigree extension and 
mutation screening has increased the number of informative members. All 10 
members with the mutation have Type 2 diabetes, one of whom was diagnosed at 
the age of 19 years. 6 other diabetic members do not possess the mutation 
(Stoffel et al 1992b), this demonstrates the genetic heterogeneity of diabetes 
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mellitus within a single pedigree. 
7.3.3 Screening of gestational diabetic subjects. 
We embarked on a study to screen for glucokinase mutations in 50 Caucasian 
subjects who had had gestational diabetes (Chapter 6). 3 of these gestational 
diabetic subjects were found to have this same mutation in exon 8. Known 
members of Pedigrees AX and BX had been excluded from this study. 
7.4 METHODS. 
There are a number of potential reasons for this high prevalence of a single 
mutation. It may be that this is a common mutation which occurs spontaneously, 
or that the probands shared a common ancestor. To differentiate the cause of the 
high prevalence of this one mutation we carried out: 
7.4.1 Pedigree extension. 
Family records were studied back to the mid to late 19th Century. 
7.4.2 Haplotype construction. 
The subjects we had found to possess the mutation were investigated using the 
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microsatellite polymorphisms GCK1 and GCK2, and haplotypes were constructed. 
7.4.3 Screening of at-risk subjects from the same geographical area. 
The at-risk subjects we investigated had a fasting plasma glucose in the range 
5.5-7.8 mmol/l, and had been entered into the Fasting Hyperglycaemia Study. 
108 subjects from Oxford were screened for this mutation in exon 8 of the 
glucokinase gene using the specific RFLP. 
7.5 RESULTS. 
7.5.1 Pedigree extension. 
After Pedigree extension we found that one of the gestational diabetic subjects is 
a member of a previously unknown branch of Pedigree AX (Figure 7.5.1). The 
gestational proband is related via her paternal grandmother who had been 
unavailable for sampling on all previous studies into this Pedigree. 
7.5.2 Haplotype construction. 
Using the microsatellite markers GCK 1 and 2, many of the subjects with the 
mutation were found to have the haplotype z+4/2 (Table 7.5.2). In those in whom 
it was not possible to assign a haplotype, the alleles did contain both z+4 and 2, 
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Figure 7.5.1 Pedigree AX showing the relationship with the gestational diabetic proband. 
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Table 7.5.2. Allele scores for the microsatellite markers GCK1 and GCK 2 for 
subjects with the Glj99 ~ Arg mutation. From these, haplotypes were constructed 
when at least one of the polymorph isms was homozygous. 
Subject GCK1 GCK2 Haplotypes 
Pedigree AX 
11-7 Z,Z+4 2,2 Z,2 Z+4,2 
IV-S Z,Z+4 2,2 Z,2 Z+4,2 
IV-19 Z,Z+4 2,2 Z,2 Z+4,2 
IV-20 Z,Z+4 2,2 Z,2 Z+4,2 
V-1 Z+2,Z+4 2, Z+2,2 Z+4,2 
Pedigree BX 
IV-S Z,Z+4 2,2 Z,2 Z+4,2 
IV-9 Z,Z+4 1,2 
IV-10 Z,Z+4 1,2 
IV-19 Z,Z+4 1,2 
IV-33 Z+4,Z+4 2,3 z+4,2 z+4,3 
V-S Z+4,Z+4 2,2 Z+4,2 
Gestationals 
KD (AX) Z,Z+4 2,2 Z,2 Z+4,2 
RW(AX) Z+4,Z+4 2,2 Z+4,2 
MB Z+4,Z+4 2,2 Z+4,2 
MA Z+4,Z+4 1,2 z+4,1 z+4,2 
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so the haplotype could have occurred. 
7.5.3 Screening of at-risk subjects from the same geographical area. 
None of the at-risk subjects were found to possess the mutation. 
7.6 DISCUSSION. 
Using linkage analysis of a MODY pedigree and mutation screening followed by 
sequencing of this pedigree, classical Type 2 diabetic subjects and Gestational 
diabetic subjects we have identified five probands who possess the same 
missense mutation in exon 8 (GI/99 ~ Arg) of the glucokinase gene. This is the 
only glucokinase mutation to be described in five separate probands. All five 
probands reside in the Oxford district, and this mutation has not been described 
outside this area. 
Pedigree extension revealed that one of the three gestational diabetic subjects 
was a member of a previously unknown branch of Pedigree AX. The gestational 
proband is related to this family via her paternal grandmother. This Pedigree had 
been classified as being a classical Type 2 pedigree (O'Rahilly et al 1988 & 1989) 
which had been found to have a glucokinase mutation. The finding of this new 
branch of the Pedigree would support the suggestion that the diabetes in the 
Pedigree members with the glucokinase mutation was early-onset and hence not 
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a different phenotype from Pedigree BX. KD had been diagnosed as having 
gestational diabetes at the age of 24 years. In addition, we tested the son of 
Pedigree member IV-5. He possesses the mutation and at the age of 19 years 
has a fasting plasma glucose of 7.1 mmoi/i. This means that two members of 
Pedigree AX had been diagnosed with hyperglycaemia before 25 years of age. 
This Pedigree could now be reclassified as being one with MODY by the criteria 
proposed by Froguel (Froguel et al 1992); autosomal inheritance and 2 members 
diagnosed before the age of 25 years. 
Construction of haplotypes for those subjects with the GCK mutation found that 
they all have the z+4/2 haplotype. This suggests that no recombination has taken 
place in recent evolutionary history. The observed frequency for this haplotype in 
British Caucasian non-diabetic controls is 17.6%, (Chapter 3) The presence of 
this mutation in these four pedigrees is therefore likely to be due to a common 
ancestor. The odds of the same haplotype occurring by chance alone if the four 
probands are unrelated is 1/183 (0.176)3 ie chance of second proband = 0.176; 
third = (0.176)2, fourth = (0.176)3 which is 0.0054. 
We investigated subjects from the Fasting Hyperglycaemia Study who reside in 
the Oxford area to discover whether this mutation was present in this at-risk 
group. This mutation was not present in 108 subjects screened using the specific 
RFLP. Despite this result, the prevalence of other glucokinase mutations may be 
increased in at-risk populations from the same area as that of the probands. 
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Using various molecular biological approaches, we have identified a missense 
mutation in the glucokinase gene which is unique to the Oxford area. Individuals 
with the same mutation have been classified as MODY, Type 2 diabetes or 
gestational diabetes depending on when they have been diagnosed. Their 
molecular diagnosis is that of Glucokinase-deficient glucose intolerance. 
Pedigree extension and the construction of haplotypes suggests that the observed 
high prevalence for this mutation is due to a founder-effect. 
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CHAPTER 8 
SCREENING OF SUBJECTS WITH TYPE 2 DIABETES, MODY, 
AND GESTATIONAL DIABETES FOR THE MITOCHONDRIAL 
TRANSFER RNA (tRNALeu(UUR) MUTATION AT POSITION 3243bp. 
8.1 INTRODUCTION 
8.2 AIMS 
8.3 SUBJECTS 
8.4 METHODS 
8.5 RESULTS 
8.6 DISCUSSION 
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8.1 INTRODUCTION. 
Type 2 diabetes may be associated with defects in mitochondrial DNA (mtDNA) 
(Ballinger et al 1992). A point mutation (A~G) at position 3243bp within the gene 
encoding the transfer RNA for leucine (tRNALeu(UUR)} has been found in some 
subjects who have maternally inherited Type 2 diabetes and/or deafness (van den 
Ouweland et al 1992; Reardon et al 1992; Remes et al 1993; Oka et al 1993; 
Kadowaki et al1993 & 1994). Diabetic subjects with the mutation may present 
with gestational diabetes (Reardon et al 1992; Alcolado et al 1994). It has been 
estimated that approximately 1-3% of Type 2 diabetic subjects with a family 
history of diabetes possess this mutation (Vionnet et al 1994; Katagiri et al 1994; 
Kadowaki et aI1994). We assessed the prevalence of this mutation in UK 
Caucasians. We screened 500 random Type 2 diabetic subjects, 748 Type 2 
diabetic subjects with a family history of diabetes, 50 subjects who previously had 
gestational diabetes and 5 MODY pedigrees, 2 of which appeared to show 
maternal inheritance in the major part of the pedigrees. 
8.2 AIMS. 
. RNALeu(UUR) t f n To investigate the contribution of the mitochondrial transfer t mu a 10 
at position 3243bp to Type 2 diabetes, MODY and gestational diabetes in UK 
Caucasian subjects. 
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8.3 SUBJECTS. 
500 random subjects with Type 2 diabetes, 748 Type 2 diabetes and a family 
history of diabetes, 50 subjects who had been diagnosed as having gestational 
diabetes and subjects from 5 MODY pedigrees were stUdied. 
The 500 random subjects with Type 2 diabetes were from the UK Prospective 
Diabetes Study. At presentation they were aged 25-65 years, with a fasting 
plasma glucose >6 mmol/l, on two occasions (UKPDS VIII 1991). A separate 
cohort of 748 Type 2 diabetic subjects with a family history of diabetes were from 
the UK Prospective Diabetes Study and had a first degree relative with diabetes. 
The subjects who had been diagnosed with gestational diabetes (GDM) were 
identified by MD Gillmer and had previously been investigated for mutations in the 
glucokinase gene (Chapter 6). The MODY subjects were from five pedigrees 
(Chapter 3;Figure 3.3.1), two of which (M and EA) appeared to show maternal 
inheritance in a major part of the pedigree. Linkage to the glucokinase gene had 
been excluded in these 5 MODY pedigrees (Chapter 3). 
8.4 METHODS. 
To screen for the mutation in the mitochondrial transfer RNA, mitochondrial DNA 
was extracted from leukocytes using the Nucleon method. DNA was amplified by 
the polymerase chain reaction (PCR) using the primers previously described (van 
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den Ouweland et a11992; Chapter 2,2.7.5) under the following conditions: 11lg 
DNA, 100J!g of each dNTP, 10 mmolll Tris-HCI (pH3.8), 50 mmolll KCI, 1.5 mmol/l 
MgCb, and 1.5 Units of Taq DNA Polymerase; initial denaturing at 96°C for 4 
minutes, then 30 cycles of denaturing at 93°C for 30 seconds, annealing at 52°C 
for 30 seconds, extension 72°C for 40 seconds, and a final extension of 72°C for 
10 minutes. PCR product was visualised on a 1.5% agarose gel with ethidium 
bromide staining. 10J!1 of the PCR product was then digested with 20U of Apa1 
and incubated at 37°C for 2 hours, followed by electrophoresis on a 3% agarose 
gel stained with ethidium bromide. Amplified mtDNA from normal and a known 
mutant (provided by Prof A Harding) were digested and run on each gel as 
negative and positive controls respectively. 
To assess the sensitivity of our procedures we screened a series of mutant 
mtDNA diluted with normal mtDNA of the same concentration (98% mutant, 80%, 
70%, 60%, 50%, 40%, 30%, 20% & 10%, and subsequently 10%, 9%, 80/0, 7%, 
6% 5%, 4% 3%, 2% & 1 %). To compliment this, we also blindly screened 3 
subjects known to have less than 5% of mutant mtDNA in their blood (provided by 
P Smith, Birmingham). Using the dilution series we were able to detect every 
sample down to 4% mutant DNA diluted with normal DNA (Figure 8.4). The 
mutation could sometimes be detected at 2%-3% , but this was not invariable. We 
were also able to detect the mutation in all 3 subjects known to possess less than 
5% of mutant mtDNA. 
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Figure 8.4 Dilution series to assess the sensitivity of the RFLP and ethidium 
bromide staining to detect the tRNALeU(UUR) mutation at position 
3243bp. 
~ 428bp 
~ 315 
~ 113 
o 40 30 20 10 9 8 7 6 5 4 3 2 
%mtDNA 
Mutant mtDNA was diluted with normal mtDNA of the same concentration. 
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B-cell function (assessed as OIoB) and insulin sensitivity (assessed %S) were 
estimated by Homeostasis Model Assessment (HOMA) (Matthews et al 1985) on 
the subjects possessing the tRNALeu(UUR) mutation at 3243bp. It should be noted 
that HOMA has imprecision of 20-25%. 
8.5 RESULTS. 
We did not detect the tRNALeu(UUR) mutation in any of the random subjects with 
Type 2 diabetes mellitus, those who had been diagnosed with gestational 
diabetes, or members of the MODY pedigrees. We detected the tRNALeu(UUR) 
mutation in 2 of the 748 Type 2 diabetic subjects with a family history of diabetes 
(Figure 8.5.1) Their pedigree trees are shown in Figures 8.5.2. Both showed a 
maternal mode of inheritance of diabetes. Their clinical characteristics are shown 
in Table 8.5.1 and clinical details showing progression of their disease is shown in 
Tables 8.5.2 and 8.5.3. Both patients were non-obese and had reduced B-cell 
function as assessed by HOMA. Subject 1 had hyperglycaemia (fpg 17.2 mmol/l) 
and required insulin therapy, whereas Subject 2 had mild hyperglycaemia (fpg 7.2 
mmol/l) and obtained normal fasting plasma glucose level on very small amounts 
of glipizide. 
8.6 DISCUSSION. 
The aim of this study was to investigate the contribution of the mitochondrial 
172 
Figure 8.5.1 Agarose gel showing RFLP analysis for the tRNALeu{UUR) mutation 
at position 3243bp. 
.. 428bp 
~ 315 
... 113 
SP N p 
SP Subject detected with the mutation 
N normoglycaemic negative control 
P positive control 
The other samples shown are from diabetic subjects with a family history of 
diabetes. 
The mitochondrial DNA mutation was detected in 2 of the diabetic subjects with a 
family history of diabetes. 
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Figure 8.5.2 Pedigree trees of the two subjects possessing the tRNA Leu(UUR) 
mutation at 3243bp. 
II II 
Subject 1 Subject 2 
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Table 8.5.1 Clinical characteristics of the two subjects found to possess the 
tRNALeu(UUR) mutation at position 3243bp. 
SUBJECT 1 SUBJECT 2 
Sex Male Female 
Age at diagnosis 38 years 36 years 
Fasting plasma glucose, mmolll 17.2 7.2 
Fasting plasma insulin, mUll 10.3 6.7 
BMI, kg/m2 17.2 22.1 
%,B, HOMA* 13.2% 51.6%, 
%S, HOMA* 26.4% 51.4% 
Deafness Reported None reported 
Current treatment Insulin therapy Diet 
Family history of diabetes Mother, NIDDM Mother, 100M 
Sister, NIODM 
"'Homeostasis model assessment (HOMA) using program supplied by JC Levy 
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Table 8.5.2 Clinical data showing progression of diabetes in Subject 1 
possessing the tRNALeu(UUR) mutation at position 3243bp. 
Subject 1 
Time Weight, Therapy fpg, fpi, mUll HOMA* 
Kg mmolll %8 
at diagnosis 52 Diet 16.7 10.3 13 
3 months 52 Diet 17.2 missing N/A 
1 year 59 23 U/day insulin 6.1 15.0 N/A 
2 years 60 27 U/day insulin 5.4 12.3 N/A 
3 years 63 34 U/day insulin 8.7 19.0 N/A 
4 years 59 20 U/day insulin 8.9 17.0 N/A 
5 years 58 27 U/day insulin 9.9 19.5 N/A 
6 years 59 27 U/day insulin 11.3 12.1 N/A 
7 years 59 29 U/day insulin 8.9 16.3 N/A 
8 years 60 33 U/day insulin 12.9 10.8 N/A 
9 years 60 32 U/day insulin 6.4 missing N/A 
*Homeostasis model assessment (HOMA) uSing program supplied by JC Levy 
HOMA* 
%S 
26 
N/A 
N/A 
N/A 
N/A 
N/A 
N/A 
N/A 
N/A 
N/A 
N/A 
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Table 8.5.3 Clinical data showing progression of diabetes in Subject 2 
possessing the tRNA Leu(UUR) mutation at position 3243bp. 
Subject 2 
Time Weight, Therapy fpg, fpi, HOMA* HOMA* 
Kg mmolll mUll %8 %S 
at diagnosis 56 Diet 7.2 6.7 52% 51% 
3 months 54 Diet 6.4 5.9 59% 60% 
1 year 49 Glipizide 4.5 4.1 95% 97% 
2.5 mg 
2 year 52 Glipizide 5.3 5.1 79% 74% 
2.5 mg 
3 year 54 Diet 7.3 17.9 99% 20% 
*Homeostasis model assessment (HOMA) uSing program supplied by JC Levy 
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tRNALeu(UUR) mutation to Type 2 diabetes, MODY and gestational diabetes in UK 
Caucasian populations. We failed to detect this particular mutation in the 500 
random Type 2 diabetic subjects, members of five MODY pedigrees, and 50 
gestational diabetic subjects. 2 of 748 Type 2 diabetic subjects who had a family 
history of diabetes were found to possess this point mutation. We are confident 
that our methods are sensitive enough to detect the majority of subjects who 
possess this mutation as we were able to reliably detect down to 4%) mutant DNA 
in the presence of normal DNA, and in all 3 samples from subjects known to have 
less than 5% of mutant mtDNA. This mtDNA mutation is unlikely to be a cause of 
MODY or gestational diabetes in UK Caucasians. 
Table 8.6. summarises the results of studies investigating the contribution of this 
mutation to Type 2 diabetes. The results for the MODY pedigrees and the 
random Type 2 diabetic subjects agree with previous studies of Vaxillaire, 
Alcolado, Otobe and t'Hart. Our finding that 0.27% of UK Caucasian Type 2 
diabetic subjects with a family history of diabetes possess the mitochondrial 
tRNALeu(UUR) mutation at position 3243 bp contrasts with the results of Kadowaki, 
Vionnet, and Kishimoto who found a prevalence of between 1.9% and 2.8% in 
their study populations. 
There are a number of possible reasons for this difference in prevalence. The 
results may reflect racial differences between Japanese and UK Caucasians. 
Although Vionnet studied Caucasians, these subjects were a different population 
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Table 8.6. Summary of studies investigating the role of the A~G tRNALeu(UUR) mutation at 3243bp in Type 2 diabetes. 
MODY pedigrees I 
I 
Random Type 2 Pedigrees 
Vaxillaire et al Saker et al Alcolado et al Otabe et al t'Hart et al Saker et al 
(1994) (1995) (1994) (1994) (1994) (1995) 
No. of positive No. of positive 
0% (0/15) 0% (0/5) 0% (0/150) 0.9% (5/550) 0.4% (2/473) 0% (0/500) 
subjects subjects 
--
Subjects with a family history 
Vionnet et al Alcolado et al Kadowaki et al Katagiri et al t'Hart et al Kishimoto et al Saker et al 
(1993) (1994) (1994) (1994) (1994) (1995) (1995) 
Family history at I east 2 fi rst at least one first degree mother \/\lith Type 2 diabetes first degree first degree 
criteria degree relatives affected sibling relative \/\lith Type 2 and deafness in relative \/\lith Type relative \/\lith 
\/\lith Type 2 \/\lith Type 2 diabetes diabetes at least 2 2 diabetes diabetes 
diabetes diabetes generations 
No. of positive 
1.9% (5/267) 1.5% (1/68) 2% (2/100) 1.4% (4/294) 10.7% (3/28) 2.8% (6/214) 0.27% (2/748) 
subjects 
(French rather than UK) and had different ascertainment criteria. Our group of 
UKPDS subjects were selected if they had a known family history in one first 
degree relative, whereas the French subjects had at least 2 first degree relatives 
with diabetes. Our protocol used ethidium bromide staining rather than 
radioactivity as a detection method. In theory this is less sensitive, but we could 
reliably detect down to 4% mutant mtDNA. 
Alcolado et al and t'Hart et al found a high prevalence of the mutation in their 
Caucasian subjects with a family history of diabetes. This may be explained by 
the small sample numbers and the ascertainment criteria. The study of t'Hart et al 
is particularly important as it shows that when stringent selection criteria are 
applied, the prevalence of the mutation can be as high as 10% • It also 
strengthens the evidence for the association of the tRNA Leu(UUR) mutation at 
3243bp with the subtype of maternally inherited Type 2 diabetes and deafness 
(MIDD). It Hart et al concluded that the previously reported prevalence of the 
tRNALeU(UUR) mutation is an over-estimation of its contribution to Type 2 diabetes. 
Our results are in agreement with this, and suggest that this mutation is not a 
common contributor to Type 2 diabetes in the UK Caucasian population and is 
supported by other workers (Alcolado et al 1994). 
The clinical data for the two subjects who are positive for this mitochondrial 
mutation are shown in Table 8.5.1. They both had an early age of diagnosis (M 
38 years; F 36 years), and were non-obese. The male was reported to be deaf 
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and had 8MI 17.2 kg/m2 , and had the "more severe" diabetes, with a fasting 
plasma glucose of 17.2mmol/l, 13.20/0 normal B-cell function and required insulin 
therapy of 35 Units per day, appropriate for a normal weight diabetic (Holman et 
al 1985). The female was not reported to be deaf and had "milder" disease, with 
BMI 22.1 kg/m2 , fpg 7.2 mmolll, 51.6%) B-cell function, and on diet therapy had a 
fasting plasma glucose of 6.4-7.3 mmol/l, and on glipizide (only 2.5mg/day) fasting 
plasma glucose of 4.5-5.3 mmoi/i. Over the 3 or 9 years follow-up available there 
was no apparent progression of severity of their disease (Tables 8.5.2 and 8.5.3). 
Reviewing the literature, diabetic subjects found to possess the tRNALeu(UUR) 
mutation show heterogeneity in the clinical phenotypes they display. Type 2 
diabetic individuals with the mutation tend to have an earlier age of onset of 
diabetes, lower 8MI, and an earlier requirement for insulin therapy (Awata et al 
1993; Kishimoto 1994; Kadowaki 1993 & 1994). 
Mutations in mitochondrial DNA provides an example of the heterogeneity of Type 
2 diabetes. Defects in enzymes within the mitochondrial apparatus involved in 
oxidative metabolism, maintenance of glucose homeostasis, or "house-keeping" 
may contribute to Type 2 diabetes. Diabetes has been found to occur in subjects 
with deletions and duplications associated with Kearns-Sayre syndrome (KSS) 
and chronic progressive external opthalmoplegia (CPEO) (Poulton et al 1994). 
Defects in enzymes coded for by mtDNA may explain the maternal pattern of 
inheritance exhibited within some Type 2 diabetic pedigrees, as mitochondrial 
DNA is solely inherited from the mother (Alcolado et al 1995). Further studies 
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may show more common genetic defects affecting mitochondrial function. 
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9.1 INTRODUCTION. 
Glucagon plays an important role in the control of hepatic glucose production and 
is involved in the regulation of insulin secretion. Glucagon action is mediated 
through its binding to a specific receptor which belongs to the superfamily of G 
protein-coupled transmembrane receptors. Mutations in the glucagon receptor 
gene located on chromosome 17q25 may therefore contribute to Type 2 diabetes. 
SSCP mutation screening, and direct sequencing identified a heterozygous 
mutation in exon 2, resulting in GGro to AGT (Gly4°~Ser) (Hager et aI1995). 
This mutation was found in 5% of French familial Type 2 diabetic patients and 
0.9%) of controls. Receptor binding studies revealed that the presence of this 
mutation results in a 67% reduction in affinity for the binding of glucagon 
compared to the "wild-type". This could playa role in the development of Type 2 
diabetes as hyperglucagonaemia increases gluconeogenesis and contributes to 
hepatic insulin resistance (Baron et al 1987; Raskin et al 1978). 
Although an association was demonstrated between the GCG-R gene mutation 
and Type 2 diabetes, genetiC linkage was only found when individuals in families 
with impaired glucose tolerance (IGT) were included (Hager et al 1995). This 
mutation removes a cutting site for the restriction endonuclease BstEII, so can 
therefore be detected as an RFLP. In an independent case-control study of 
Sardinian subjects, they failed to show a statistically significant association. No 
clinical data were available for those individuals who possessed the mutation. A 
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rare phenotypic subgroup of Type 2 diabetes can therefore not be excluded. 
The results of Hager et al need replicating in an independent data set. Full 
clinical details are required, to distinguish whether those subjects possessing the 
mutation are phenotypically different from classical Type 2 diabetic subjects. 
9.2 AIMS. 
To attempt to replicate the results of the association of the GCG-R gene mutation 
with Type 2 diabetes in UK Caucasian subjects. To examine the phenotypes, to 
determine whether those with the mutation exhibited features of classical Type 2 
diabetes. To investigate whether this mutation was present in subjects who have 
an increased risk of developing diabetes by screening individuals who had 
previously had gestational diabetes, and individuals with fasting hyperglycaemia, 
but without diabetes as defined by WHO criteria. 
9.3 SUBJECTS. 
The subjects investigated were as follows: 
a. 274 Caucasian Type 2 diabetic subjects from the Oxford centre of the 
UKPDS (UKPDS VIII 1991). 
b. 100 individuals who had previously been diagnosed as having gestational 
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diabetes. 
c. 69 individuals with fasting hyperglycaemia (>5.5, <7.8 mmolll) on two 
separate occasions who had been recruited as part of the Oxford centre of 
the Fasting Hyperglycaemia Study (FHS). None of these had overt 
diabetes, and none were receiving oral hypoglycaemic agents at the time 
of recruitment. 
d. 5 MODY pedigrees (Chapter 3). 
e. 17 nuclear pedigrees who were not linked to the glucokinase gene (Cook 
et al 1992). Affected subjects had Type 2 diabetes or impaired glucose 
tolerance, as shown by an intra-venous glucose tolerance test. 
f. 146 non-diabetic controls were recruited as part of the UKPDS. 
9.4 METHODS. 
Exon 2 was amplified using the primers described by Hager et ai, and shown in 
Chapter 2; 2.7.6. Genomic DNA was amplified in a total volume of 25fJ.1. PCR 
conditions were: initial denaturation at 94°C for 5 minutes; 32 cycles of 94°C for 
90 seconds, 55°C for 1 minutes, and 72°C for 30 seconds with a final extension at 
72°C for 10 minutes. PCR product was checked on a 1.5% agarose gel. 7~d of 
the PCR product was digested with 5U of BstEIi at 60°C for 2 hours. The samples 
were then loaded onto a 3% agarose, 10;0 NuSieve gel with ethidium bromide 
staining and electrophoresed. Digestion products were visualised using UV-light. 
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9.4.1 Statistical Analysis 
The Fisher's right-tailed exact test was used to assess whether there was 
significant differences in the frequency of the mutation in the diabetic groups and 
non-diabetic controls. 
Differences between the clinical characteristics of UKPDS Type 2 diabetic 
subjects with and without the mutation were analysed using the students t-test. 
9.5 RESULTS. 
Mutation of the GCG-R gene was present in 7/274 Oxford UKPDS subjects and in 
0/146 UKPDS non-diabetic controls. The results showed an association of the 
mutation with Type 2 diabetes (diabetics vs non-diabetic controls, 2.6% vs 0%; 
p=0.049). The clinical characteristics of the patients from the UKPDS Type 2 
diabetes study in Table 9.5 .1 show no differences in phenotype between those 
with and without the GCG-R mutation. 2 patients with gestational diabetes were 
found to possess the mutation (GDMs vs non-diabetic controls, 2% vs 0%). Data 
was available for 50 of the gestational diabetic subjects who at present have mild 
hyperglycaemia (Table 9.5.2). There were no differences between the subject 
with or the 49 subjects without the mutation with respect to the characteristics of 
pregnancy (including duration of gestation, number of previous miscarriages and 
the weight of the child), or clinical characteristics at follow-up (including body 
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Table 9.5.1 Clinical characteristics of patients in the UKPDS Type 2 diabetes 
study. 
Type 2 Diabetic subjects Type 2 Diabetic subjects 
negative for the GCG-R positive for the GCG-R 
gene mutation (n=267). gene mutation (n=7) 
Age, years. 52.3 (+1-8.6) 52.3 (+1-8.4) 
Body Mass Index, Kg/m2 . 29.2 (+1-5.7) 32.3 (+1-6.4) 
Fasting plasma glucose, 
12.6 (+1-4.2) 13.0 (+1-2.5) 
mmolli. 
Fasting plasma insulin, mUll. 14.2 (8.2 to 24.5) 21.1 (17.8 to 25.1)* 
Insulin sensitivity, %5. 21.5 (12.7 to 36.5) 14.4 (11.7 to 17.7)** 
p-cell function, %8. 33.6 (15.3 to 73.8) 38.2 (25.8 to 56.4) 
Waist/hip ratio 0.92 (+1-0.09) 0.94 (+1-0.10) 
Results adjusted for sex, expressed as mean (standard error). Homeostasis model assessment 
(HOMA) using program supplied by JC Levy. Differences tested using students t-test. Fasting 
plasma insulin, insulin sensitivity and p-cell function expressed as geometric mean (1 standard 
error mean) comparisons between groups for these variables vvere performed on log transformed 
data .. * p=O.08; ** p=O.06 
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Table 9.5.2 Characteristics of the gestational diabetic subjects currently with 
mild hyperglycaemia. 
Gestational diabetic Gestational diabetic 
subjects negative for the subject positive for the 
GCG-R mutation (n=49) GCG-R mutation (n=1) 
Family history in first degree 
32%) yes yes 
relatives 
Characteristics of pregnancy GDM diagnosed during 
third preonancy 
insulin treatment 88%) (44/49) during third pregnancy 
No. of weeks gestation 38.7 +1- 2 38.3 +1- 0.5 
mean weight of children 7.32 +1- 1.43 8.0 
number of children 2.7 +1- 1.3 3 
number of miscarriages 0.6 +1- 1.1 0 
Characteristics on follow-up 
Age, years 38.6 +1- 6.2 33 
No of years since initial 
10.6 +1- 5.9 10.0 
diaonosis of GDM 
mean 8MI, Kg/m2 27.8 +1- 6.1 28.5 
mean fpg, mmol/l 7.0 +1- 3.7 5.7 
mean fpi, mUll 10.9 (6.19-19.1) 11.7 
CIGMA%B 83.5 (55.3-117.5) 117% 
CIGMA %S 42.7 (21.5-61.0) 32% 
Fasting plasma insulin, insulin sensitivity and J3-cell function expressed as geometnc mean (1 
standard deviation range). 
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mass index, fasting plasma glucose or fasting plasma insulin). 1 of the subjects 
with fasting hyperglycaemia was found to possess the mutation (FHS vs non-
diabetic controls, 1.4% vs 0%). The frequency of the mutation in these two 
groups combined is 3/169 (combined vs non-diabetic controls, 1/57 vs 0/149), a 
similar frequency to that in Type 2 diabetic subjects, but it is not a significant 
difference from the non-diabetic controls (p=0.153). 
Subjects in one of the nuclear pedigrees were found to possess the GCG-R 
mutation. The mutation segregated with Type 2 diabetes and IGT and was not 
found in the non-diabetic mother and sibling. The pedigree tree is shown in 
Figure 9.5, and the available clinical data is shown in Table 9.5.3. 2 of the 3 
subjects with the GCG-R mutation have diabetes. The third subject has normal 
fasting plasma glucose, but glucose intolerance as assessed with CIGMA. These 
three subjects all have a low normal B-cell function. None of the members of the 
MODY pedigrees were found to have the GCG-R mutation 
9.6 DISCUSSION. 
We have confirmed the association of a mutation of the GCG-R gene with Type 2 
diabetes. This mutation was present in 2.6% of Oxford UKPDS patients and 0% 
of non-diabetic UKPDS control subjects. Those subjects positive for the mutation 
showed clinical features of classical Type 2 diabetes. Compared to those 
subjects without the mutation, there were no significant differences in age at 
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Figure 9.5 Agarose gel and Pedigree tree of the Nuclear pedigree J10, showing 
the inheritance of the Gly40 ~Ser mutation in the glucagon receptor 
gene. 
II 
/ 
1 
N,M 
N,M N,N 
2 3 
N,N N,M 
IGT 
~ 196bp 
~ 108 
~ 88 
N - normal allele; M - mutant allele; IGT - impaired glucose tolerance; arrow 
indicates proband 
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Table 9.5.3 Clinical data for the three siblings from Nuclear Pedigree J1 o. 
Subject Sex Age, 8MI, fpg, CIGMA CIGMA CIGMA 
years Kg/m2 mmol/l apg, mmolll 0/08 %S 
111 Female 36 26.4 N/A N/A 31.0 122.8 
112 Female 51 N/A 5.36 7.93 126 72.1 
113 Female 45 N/A 5.24 10.58 57.0 70.9 
8MI - body mass index; fpg - fasting plasma glucose; CIGMA - continuous infusion of glucose 
model assessment; apg - attained plasma glucose (CIGMA 1 hour glucose); 
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diagnosis, body mass index, fasting plasma glucose, or HOMA estimates 
(Matthews et al 1985) of B-cell function or insulin sensitivity. 
Genetic linkage of the GCG-R gene mutation to Type 2 diabetes had previously 
been found only when data was combined from individuals with IGT. Hager et al 
speculated that this mutation may playa role in the early development of some 
forms of Type 2 diabetes by increasing the susceptibility to IGT. We therefore 
investigated the prevalence of this mutation in individuals who had been 
diagnosed with gestational diabetes, and those who had fasting hyperglycaemia. 
Members of these groups are at an increased risk of developing Type 2 diabetes 
in later life. The observed frequency of the GCG-R gene mutation in these two 
groups combined (1.8%) was similar to that found in Type 2 diabetes (20/0), but 
was not significantly different from non-diabetic controls. A signifcant difference 
would have been consistent with the hypothesis that this mutation increases the 
susceptibility to IGT which then progresses to Type 2 diabetes. This hypothesis 
is supported by one of the nuclear pedigrees though. The GCG-R gene mutation 
was found to segregate with Type 2 diabetes and IGT in Pedigree J1 0 (Figure 
9.5). 
Glucagon receptors are found in the liver and ~-cells. In the liver, glucagon 
stimulates glycogenolysis and gluconeogenesis resulting in an increase in plasma 
glucose concentration (Magnuson et al 1995). Glucagon also stimulates insulin 
secretion which partially regulates the increased production of glucose from the 
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liver. In normal controls, glucagon has been shown to contribute to the 
maintenance of hepatic glucose output (Magnuson et al 1985). In type 2 diabetic 
subjects, glucagon levels are involved in sustaining more than 50% of the 
increased basal output of hepatic glucose (Baron et al 1987). 
Hager et al conducted functional analysis studies and found that the receptor had 
reduced affinity for glucagon in the presence of the mutation. These results were 
for the homozygous form, but only the heterozygous GCG-R mutation has been 
detected. A mutation could result in an increased turnover of the glucagon-
receptor, a direct decrease on the physiological response to glucagon, or another 
mechanism. Hager et al had preliminary data (unpublished) which suggested that 
the baby hamster kidney cAMP response to glucagon was lowered. This would 
support a decrease in the physiological effect of glucagon in the presence of the 
mutant GCG-R. 
The trend to higher fasting plasma insulin and insulin sensitivity in those subjects 
with the GCG-R mutation was not statistically significant, and probably reflects the 
increased 8MI in these patients, or the relatively small number of subjects 
involved. As glucagon appears to act mainly through the GCG-R (Kawai et al 
1995), a mutation which resulted in weaker glucagon binding and a decrease in 
cAMP response might be expected to produce a decreased rather than increased 
physiological effect of glucagon. 
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Alternatively, if the mutation decreases the stimulatory effect of glucagon on the 
~-cell, the mutation may result in a decrease in the insulin secretory respo nse. 
The clinical data did not indicate that those with the mutation had less f3-cell 
function than other Type 2 diabetic subjects. 
The data from the Nuclear pedigree shows linkage of diabetesllGT with the 
mutation, suggesting a prominent role. On the other hand, the mutation is also 
found in non-diabetic subjects (Hager et al 1995; Gough et al 1995). It is possible 
that the Gly40 ~Ser GCG-R mutation is in linkage disequilibrium with another, as 
yet unknown, mutation in or near the GCG-R gene. This hypothesis would 
explain why the described mutation segregates in pedigrees, where it is linked 
with a pathogenic mutation, but can also be found in the normal population 
(10/1122 normal subjects Hager et al 1995; 1/279 normal subjects Gough et al 
1995), where it has not segregated with the pathogenic mutation. 
The positive association without a pathogenic role for the mutation, and linkage 
disequlibrium could have occurred due to genetic admixture. The group studied 
here are well-selected, but such problems can occur even in populations 
previously thought to be homogeneous, ie Nauruans. This explanation may not 
wholly be correct, as these cohorts of subjects have been used in previous 
population association studies with negative results. This would suggest that they 
are well-matched. Unlike this study though, they did not utilise bi-allelic markers 
which are more sensitive to genetic admixture than CA repeats with multiple 
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alleles. It would be useful to construct a model of the GCG-R molecule to assess 
the effect of the mutation on its molecular mechanism. Kinetic studies should also 
be conducted to discover how this GCG-R mutation affects the function of the 
GCG-R and the physiological response to glucagon. Measurements of the 
glucagon concentration in the subjects who possess the mutation could be 
compared to matched Type 2 diabetic and non-diabetic controls to assess 
whether there is a compensatory increased response in glucagon secretion. 
We have confirmed an association of the glucagon receptor gene mutation 
(Gly4o ~Ser) with Type 2. Despite this, there is insufficient evidence to define a 
role for this mutation in Type 2 diabetes. This study illustrates the difficulty in 
establishing the role of a base sequence variation, even if it is known to alter the 
amino acid sequence. This remains one of the major challenges to defining the 
molecular genetics of Type 2 diabetes. 
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CHAPTER 10 
DISCUSSION 
The work described in this dissertation has studied a number of different subject 
groups to investigate the molecular genetics of Type 2 diabetes, with particular 
emphasis on the contribution of glucokinase, a specific mitochondrial DNA 
mutation, and a mutation in the glucagon receptor gene. 
Mutations in the glucokinase gene had been found to be the cause of 
hyperglycaemia in subjects with MODY, a subgroup of Type 2 diabetes (Froguel 
et a11992b; Hattersley et al 1992b). This subgroup had been studied as it is 
clinically well-defined, and its early age of onset enables the collection of large 
multi-generation pedigrees for genetic studies. We investigated the inheritance of 
two polymorphic microsatellite markers at the glucokinase loci in another five 
British MODY pedigrees. The results of this linkage study revealed that defects in 
the glucokinase gene are an unusual cause of diabetes in British MODY 
pedigrees with symptomatic hyperglycaemia. The results further highlighted the 
heterogeneity of MODY, and further studies have shown that there are at least 
four genes involved in MODY. In addition to glucokinase, loci near the ADA gene 
(Bell et al 1991) on chromosome 20, and recently loci on chromosome 12q 
(MODY3) (Froguel et al 1995; Dronsfield et al 1995), have been to be linked to 
diabetes. The genes and mutations responsible have yet to be identified. There 
is at least one other gene contributing to MODY as some pedigrees are not linked 
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to any of these three loci. 
Following identification of glucokinase mutations being shown to be responsible 
for members of the MODY subgroup of Type 2 diabetes, we completed a 
population association. No association of the glucokinase locus with Type 2 
diabetes in the UK Caucasian population was found. This result suggested that a 
single major mutation in or near the glucokinase gene is not a major cause of 
Type 2 diabetes in this population. It doesn't negate a role for a number of minor 
mutations, or a major role in certain patient populations. Mutation screening has 
identified over 20 different glucokinase mutations in MODY, but has shown that 
pathogenic mutations in Type 2 diabetes are rare. 
The development of a robust method for SSCP analysis, enabled us to screen for 
mutations. We showed that mutations in the glucokinase gene can contribute to 
the pathogenesis of gestational diabetes. Diagnosis based on the identification of 
this genetic lesion enabled us to predict a good prognosis based on the clinical 
observations in affected MODY subjects possessing this particular mutation. 
Using various molecular biological approaches, five probands had been identified 
with the same missense mutation in the glucokinase gene. This particular 
mutation was unique to the Oxford area. Individuals with the same mutation had 
been classified as MODY, Type 2 diabetes, or gestational diabetes depending on 
when they had been diagnosed. Their molecular diagnosis is that of glucokinase-
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deficient glucose intolerance. Pedigree extension and the construction of 
haplotypes suggested that the observed high prevalence for this mutation was 
due to a founder-effect. The data suggest unsuspected glucokinase mutations in 
extended family members may be more common than is realised. 
From these studies, we can conclude that defects in the glucokinase gene are not 
a major contributor to Type 2 diabetes in UK Caucasians, but may have a 
prominent role in subgroups of this disease. More studies need to be conducted 
to determine whether there is a role for defects of the glucokinase promotor 
region, and any modifying genes. The effect of mutations of hepatic glucokinase 
on liver function have yet to be fully assessed. If there is reduced hepatic 
glucokinase activity, it might result in insulin resistance in the liver. Insulin 
resistance was not found to be increased in subjects with the Gli99 ~Arg mutation 
(Hattersley et al 1992b; Page et al 1995). 
Methods may be developed to rapidly screen for mutations. This will probably be 
achieved by an automated system. Subjects with a phenotype similar to that of 
glucokinase-deficient glucose intolerance may then be tested for defects of the 
glucokinase gene. This molecular genetic approach to diagnosis may then 
provide information on the prognosis and aid treatment. 
Under aerobic conditions, 95% of ATP synthesis in ~-cells is supplied by the 
mitochondrial respiratory chain. Defects in mitochondria may therefore affect 
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insulin secretion and glucose homeostasis The tRNALeu(UUR) mutatl'o t 't' 
. n a POSI Ion 
3243 bp has been found in a number of pedigrees with diabetes mellitus and/or 
deafness. We investigated the contribution of this tRNALeu(UUR) mutation in the UK 
Caucasian population. We found that 0.27% (2/748) of Type 2 diabetic subjects 
with a family history of diabetes possess this mutation. This finding contrasts with 
the prevalence of 1.9-2.8% in other study populations (Vionnet et al 1994; Katagiri 
et al 1994; Kadowaki et al 1994). Differences in race, or the ascertainment of 
subjects may be responsible for this. The clinical data of our two positive subjects 
and a review of the literature shows that diabetic subjects possessing the 
tRNALeU(UUR) mutation show heterogeneity in their clinical phenotypes. There is a 
suggestion that Type 2 diabetic individuals with the mutation tend to have an 
earlier age of onset of diabetes, lower 8MI, and an earlier requirement for insulin 
therapy. 
Further investigations of the relationship between mitochondria and diabetes may 
continue to utilise RFLP analysis, mutation screening and direct sequencing of 
the mitochondrial genome. A recent finding is that subjects with Kearns-Sayre 
syndrome and mtDNA duplications often have diabetes (Poulton et al 1994). This 
is not the first time that duplications have been reported to be associated with 
diabetes. The improvement in the DNA polymerases used in peR will enable 
amplification of up to 10kb, thus allowing relatively rapid screening of the 
mitochondrial genome. It may then be possible to establish whether there is a 
role for mtDNA duplications in Type 2 diabetes. The interaction of nuclear 
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encoded mitochondrial enzymes including manganese superoxide dismutase, is 
still to be fully investigated. 
We confirmed the association of the heterozygous mutation in the glucagon 
receptor gene (Gly4o ~Ser) with Type 2 diabetes. It is difficult to interpret the 
putative physiological abnormality and how the defect results in diabetes, unless 
the receptor defect hinders the glucagon stimulation of Il-cell secretion. This 
mutation may be in linkage disequilibrium with another mutation in, or near the 
glucagon-receptor gene, such as the promotor region. The physiology of 
glucagon would suggest over-expression of the receptor in the liver might lead to 
hyperglycaemia. It has been suggested that these are false- positive 
associations, due to genetic admixture between the diabetic and control subjects. 
This explanation may not be wholly correct as the subjects studied in Chapter 9 
have been used in previous population association studies with a negative result 
(Chapter 4; Zhang et al 1994). Previous studies though, utilised CA repeats with 
multiple-alleles rather than bi-allelic markers which are much more sensitive to 
demonstrating genetic admixture. The contribution of this mutation to Type 2 
diabetes still needs to be clarified. 
Future Studies. 
The discovery of further gene defects contributing to Type 2 diabetes will require 
the identification of suitable subjects to study. Physiological studies will help to 
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differentiate the phenotypic heterogeneity and define further subgroups suitable 
for investigation. One approach may be the study of genes responsible for 
diabetic complications such as cardiovascular disease and the relationship with 
cholesterol. Family studies are still important, but to overcome the problems 
involved with obtaining large pedigrees the collection of sib-pairs has been 
proposed. This strategy also has inherent problems but will still be of great value. 
There is the possibility of establishing a UK BOA-coordinated collection for these 
subjects, as has already been successful with Type 1 diabetes and MODY 
pedigrees. 
There has been an advancement in the technology which may be applied to 
linkage studies. Genome-wide screening using the polymorphic microsatellite 
markers is now a realistic proposition. This requires no knowledge of the 
biochemical defect, or the identification of a candidate gene. The polymorphic 
markers are fluorescently labelled, and many markers can be run on the same gel 
and subsequently analysed. The equipment used increases the amount of 
information which can be obtained at a given time and hence the speed. This 
approach has been successful in Type 1 diabetes (Davies et al 1994). It has 
recently been applied to Type 2 diabetes with the finding of linkage to 
chromosome 12q in MODY pedigrees (Froguel et al 1995; Dronsfield et al 1995). 
Now MODY3 has been isolated to this region, studies will now progress to identify 
the gene involved and the genetic defect contributing to the disease. The work 
carried out to determine the genetic lesion near the ADA loci illustrates the 
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possible problems which will be encountered during this project. 
The mutations which have been shown to contribute to Type 2 diabetes to date 
are only responsible for a small proportion of this polygenic disease. Elucidating 
the genes responsible for the common polygenic form of Type 2 diabetes remains 
a difficult challenge. Power calculations suggest that very large data sets will be 
required to establish the role of a new gene in Type 2 diabetes. This will require 
collaboration between research groups and a highly mechanised approach to 
genetic analysis. Success will depend on clinical and physiological studies, 
animal studies and the application of new molecular genetics techniques. 
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